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Moraxella catarrhalis is an upper respiratory pathogen often implicated as the cause 
otitis media infections, as well as exacerbating chronic obstructive pulmonary disease. 
One of the human receptors identified for Moraxella catarrhalis is Carcinoembryonic 
antigen-related cell adhesion molecule 1 (CC1), normally the surface adhesins UspA1 
and UspA2V use the CC1 specific binding sequence within the previously identified 
rD-7region of UspA1 to interact with CC1. ATCC25240 is a strain of Moraxella 
catarrhalis which lacks the rD-7 region within its UspA1. This study revealed that a 
variant of ATCC25240 dubbed MX13L, which also lacks the rD-7 regions binds to 
CC1. The unknown adhesin present in MX13L interacted with CC1 in a heat modifiable 
manner. Using a combination of bioinformatics and the ez tn5 transposon to generate 
a transposon library of MX13L in conjunction with immune overlay assays, we 
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 Background information 
Moraxella catarrhalis is a gram-negative diplococcal bacterium of the order 
Pseudomonadales. It has been predominantly involved in upper respiratory tract 
infections such as otitis media but in recent years it has been implicated in the 
exacerbation of COPD. One of the major host cell receptors of Moraxella catarrhalis 
is human Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CC1). 
Although Ubiquitous surface protein (Usp)A1 as well as UspA2V, identified as the main 
bacterial proteins which interact with CC1 are well understood, recent experiments 
have indicated that there may be another yet unknown CC1 binding protein. This 
project aims to identify the novel CC1 ligand. 
 
 Taxonomy 
Moraxella catarrhalis was first described in 1896 by R.J. Pfeiffer, who named it 
Micrococcus catarrhalis (Murphy, 1998) (Catlin, 1990). Since the discovery this 
bacterium has been reclassified numerous times. First in 1963 when Burges nitrate 
reduction reactions showed that Micrococcus catarrhalis could be split into to two 
distinct species Neisseria cinerea and N. catarrhalis (Verduin et al., 2002) (Berger, 
1963). Then in the 1970s when DNA hybridisation studies showed little homology with 
‘true’ Neisseria species it was renamed Branhamella catarrhalis (Murphy, 1998) 
(Catlin, 1970). In 1984 B. catarrhalis was reassigned to the genus Moraxella although 
many prefer the old name Branhamella and argued that the genus Moraxella should 




sequencing proved that Moraxella catarrhalis was closely related to M. lacunata and 
more closely related to Acinetobacter than to Neisseria thus Moraxella catarrhalis is 
now the widely accepted name (Pettersson et al., 1998) (figure 1). 
Along with determining that Moraxella catarrhalis is in fact a Moraxella species, 16s 
ribosomal data and restriction length polymorphism analysis has determined that there 
are 2 distinct evolutionary lineages of Moraxella catarrhalis (Bootsma et al., 2000). 
The seroresistant line contains 16S ribotype 1 strains, whilst the serosensitive strains 
have 16S ribotype 2 or 3 (Earl et al., 2016) (de Vries et al., 2013) (Bootsma et al., 
2000). Of the two lineages the seroresistant strains have a been isolated from infected 
individuals, suggesting a more pathogenic nature, they display both efficient 
adherence to epithelial cells as well as complement resistance (Verhaegh et al., 2008).  
Compared to the seroresistant strains the serosensitive strains display reduced 
adherence to respiratory epithelial cells as well as sensitivity to complement mediated 
killing. Although the seroresistant lineage is more pathogenic than the serosensitive 
lineages, whole genome analysis of clinically relevant seroresistant strains with varied 
disease profiles revealed limited genetic diversity between seroresistant strains (Wirth 
et al., 2007). In comparison the serosensitive lineage is much more genetically diverse 
and the genetic drift between strains appears to be mainly caused by point mutations, 








Figure 1 Taxonomy of Moraxella catarrhalis. 
  
This image demonstrates the genus level relation between Moraxella catarrhalis and M. lacunata, and 
the familial relation between Moraxella catarrhalis and Acinetobacter species. The distant association 
of Moraxella catarrhalis and Neisseria species is also evident, as the species diverge at class level. 










Following its discovery this gram-negative diplococcal bacterium was regarded as a 
harmless commensal of the upper respiratory tract (Ariza-Prota et al., 2016). In the 
last few decades it has emerged as a significant pathogen of the upper and lower 
respiratory systems both in healthy and immunocompromised individuals (Verduin et 
al., 2002). The carriage rates of Moraxella catarrhalis are highest in children; 77% 
become colonised in the first five years, although only a small portion (approximately 
9%) of these isolates are of clinical significance (Verduin et al., 2002). In contrast to 
the high carriage rates in children, Moraxella catarrhalis only colonises a small portion 
of adults (1-3%) but around 30% of these cases become clinically relevant 
(Vaneechoutte et al., 1990). 
  
1.3.1 Diseases in children 
In children this bacterium is one of the most prevalent causes of otitis media, along 
with Streptococcus pneumoniae and Haemophilus influenzae. Although estimates put 
Moraxella catarrhalis as the sole cause of 15-20% of acute otitis media cases, PCR 
detected in up to 47% of bacterial cultures obtained from middle ear fluid (Murphy and 
Parameswaran, 2009) (Sillanpää et al., 2016). Due to the age groups at most risk, and 
the recurrent nature of otitis media infections, it is a significant cause of morbidity and 
burden on health services, estimated to cost upwards of £200 million each year to 





1.3.2 Diseases in adults 
Infections in adults tend towards those with already compromised immune systems, 
causing sinusitis in the upper respiratory tract and exacerbating chronic obstructive 
pulmonary disease (COPD) in the lower (Ramadan, Ibrahim, Shaheen and Ali, 2017). 
COPD is the fourth most common cause of death worldwide, and prevalence in the 
UK has increased by 27% in the last decade (WHO, 2016) (British Lung Foundation, 
2019). Recent research has shown that Moraxella catarrhalis can be isolated more 
often from sputum samples than either Streptococcus pneumoniae or Haemophilus 
influenzae, colonising approximately 32% of patients with COPD (Parameswaran et 
al., 2009) (Leung et al., 2017) (Perez and Murphy, 2017). Although not all colonisation 
lead to exacerbation, about 10% of all COPD exacerbation is caused by M. catarrhalis. 
There are 1.2 million people living with COPD in the UK and exasperation caused by 
Moraxella catarrhalis costs the NHS approximately £190 million to treat per annum 
(British Lung Foundation, 2019). 
  
1.3.3 Septicaemia and bacteraemia 
Patients who are hospitalised for prolonged periods, along with those in intensive care 
units and the very young or elderly, often have a poor prognosis when suffering from 
a Moraxella catarrhalis infection (Constantinescu, 2019). Cases of bacteraemia, 
meningitis and sepsis has been reported within the at-risk groups. These patients have 
high mortality rates of about 21% (Ioannidis et al., 1995). When Moraxella catarrhalis 
causes bacteraemia, an associated respiratory infection is usually found. Severe 




al., 1995). Although Moraxella catarrhalis survives in the bloodstream better than 
Neisseria meningitidis, cases of bacteraemia have been infrequently reported. This 
may be due to misdiagnosis as Moraxella catarrhalis is both very similar to Neisseria 
species and has only recently been identified as a significant pathogen.  
  
 Antibiotic resistance 
Prior to its designation as a significant pathogen of the respiratory tract Moraxella 
catarrhalis was regarded as a harmless commensal which was easily treated via 
penicillin (Lacy, Berk and Berk, 2017). In the last 40 years this opinion has been 
revised. In 1976 a Swedish sputum isolate of Moraxella catarrhalis was reported to be 
resistant to penicillin and ampicillin (Malmvall, Brorsson and Johnsson, 1977). Further 
tests revealed it to be a novel beta-lactamase. The appearance of this novel resistance 
gene occurred practically simultaneously around the world and today over 95% of 
isolates produce one of 2 beta-lactamases; BRO-1 or BRO-2 (Shi et al., 2018) (Khan 
et al., 2009). Although these proteins are functionally identical with both genes binding 
the same substrate and only differing in sequence by a single amino acid residue 
(Glycine for Aspartate), BRO-1 confers a higher MIC than BRO-2 (Bootsma et al., 
1996) (Uniprot, 2019). This difference in level of resistance is probably due to 
differences in the promoter regions resulting in a 3-fold increase in BRO-1 production 
(Schmitz et al., 2002). 
Along with beta lactam resistance, Moraxella catarrhalis is also resistant to some 




UK demonstrate resistance to cefaclor and 5% are resistant to cefuroxime (Khan et 
al., 2009). 
 
 Vaccine development  
Moraxella catarrhalis is a clinically relevant pathogen which causes significant 
morbidity and mortality, as well as burdening health care systems worldwide (Perez 
and Murphy, 2019). Due to the widespread resistance to beta lactams within the 
Moraxella catarrhalis population as well as rising resistance to second generation 
antibiotics, it has become evident that a preventative vaccine is necessary.  
1.5.1 Challenges  
When designing a vaccine, it is important to consider the following criteria for antigen 
selection (Thibau et al., 2019) (Ren and Pichichero, 2015) (Raynes et al., 2018): 
• Is the epitope expressed on the surface of the bacteria?  
• Is the epitope conserved among different strains? 
• Is the antigen expressed in vivo at sites of pathogenesis? 
• Is the antigen immunogenic? 
• Does the antigen induce a protective immune response? 
With regards to Moraxella catarrhalis there are a number of limitations to the 
development of an effective vaccine (Ren and Pichichero, 2015). In silico and in vitro 
studies of Moraxella catarrhalis have identified many adhesins (see 1.6) which satisfy 
the first three criteria for antigen selection (Grandi, 2010). Although these antigens 
have been shown to be immunogenic, very few of the antibodies generated have been 
assessed for functionality (Perez and Murphy, 2017). Another factor is that there is no 




antibodies. Another factor to consider is that many of the identified surface antigens 
such as UspA and MID/Hag are subject to phase variation. Another limitation to the 
development of a vaccine is the lack of animal models (Perez and Murphy, 2017). 
Moraxella catarrhalis is a human restricted pathogen which means that it is difficult to 
study the effects of a potential vaccine candidate in vivo.  
The main animal model used to study Moraxella catarrhalis infections in vivo is via 
inoculating mice (Ruckdeschel, Brauer, Johnson and Murphy, 2009). Unfortunately, it 
is not possible to colonise mice with Moraxella catarrhalis and naive mice will usually 
clear a Moraxella catarrhalis infection in 24hrs (Smidt et al., 2013). Although this limits 
testing windows to just a few hours the results obtained from such tests are consistent 
and reproducible, which is why mice remain the model of choice for Moraxella 
catarrhalis infections.  
Chinchillas are also used to study otitis media infections (Shaffer et al., 2013). Unlike 
mice which rapidly clear Moraxella catarrhalis, the nasopharynx of chinchillas is 
colonised for approximately one week by Moraxella catarrhalis. The main limitation to 
the chinchilla model is that not all of the animals challenged with Moraxella catarrhalis 
will develop otitis media. The main benefit to the chinchilla model is that a multispecies 
infection can be established, which better simulates a natural infection (Perez et al., 
2014). This may enable a better understanding of how effective a potential vaccine will 
be, although only in the latter stages of research as multiple species also add another 
layer of variability to any results.  
One solution to the lack of animal models is to use so called ‘humanized’ mice, which 
are immune-compromised mice that have been grafted with human immune cells or 




Moraxella catarrhalis and even produce some pathogen-specific human immune 
responses (Rämer et al., 2011). 
1.5.2 Benefits  
Much like the 23 valent pneumococcal and MenAWCY vaccines, any Moraxella 
catarrhalis vaccine will most probably be a multivalent vaccine containing a variety of 
surface expressed proteins. This would facilitate immune clearance and stimulate 
protection by blocking multiple pathogenicity targets.  
Vaccination against Moraxella catarrhalis is rapidly becoming a necessity and has the 
potential to alleviate a massive socioeconomic burden. A Moraxella catarrhalis vaccine 
could prevent 10% of all COPD exacerbations and given the role that Moraxella 
catarrhalis plays as a co pathogen the results of a Moraxella catarrhalis vaccine could 
be much broader than expected.  
 
 Adhesion mechanisms 
Moraxella catarrhalis colonises mucosal surfaces in both the upper and lower 
respiratory tract, colonisation is a multifactorial event with a range of proteins involved, 
both host and bacteria (de Vries et al., 2009).  
  
1.6.1.1 Type IV pili 
Type IV pili (TFP) mediate long range interactions between Moraxella catarrhalis and 




et al., 2009). The pili produced by Moraxella catarrhalis are highly conserved with little 
variation; only 2 antigenic variants of pilA are evident between strains (Luke-Marshall, 
Sauberan and Campagnari, 2011). TFP deficient mutants have reduced virulence due 
to lower rates of colonisation as well as impaired biofilm formation (Luke et al., 2007).  
 
1.6.1.2 McaP  
McaP is a conventional autotransporter (see section 1.5.2) which displays adhesion, 
lipolytic, esterase and phospholipase B activity (Timpe et al., 2003). Knockouts of this 
62kDa protein display reduced adhesion to A549 epithelial cells and lack any esterase 
activity. The adhesive domain of this protein is located in the 12 stranded beta-barrel 
N-terminal passenger region (Lipski et al., 2006).  
  
1.6.1.3 OMP CD 
OMP CD is a porin like protein which adheres to middle ear mucin and A459 cells. 
This heat sensitive protein consists of a beta barrel anchor, a linker region and a C-
terminal domain (Murphy, Kirkham and Lesse, 1993). Bioinformatics analysis 
demonstrates that both the beta barrel and linker regions are required for adhesion to 






The Moraxella catarrhalis filamentous haemagglutinin-like Mha proteins MhaC, 
MhaB1, and MhaB2 are part of a two-partner secretion system, whereby MhaC forms 
a porin like structure which facilitates the transport of the associated MhaB1 and 
MhaB2 proteins across the outer membrane. These proteins mediate the attachment 
to HEp2, Chang, and 16HBE14o− cells (Balder et al., 2007) (Guérin et al., 2017). 
  
1.6.1.5 Lipid oligosaccharides 
Lipid oligosaccharides (LOS) are proteins which form much of the outer membrane of 
M. catarrhalis. There are 3 serotypes of LOS and they all have the same fundamental 
structure, a lipid A molecule connected to the oligosaccharide core via a kdo residue, 
only differing in their R groups (Holme et al., 1999). LOS A is the most prevalent 
serotype, found in 72% of strains, although most of these strains are isolated from 
children. LOS B and C are found in approximately 21% and 2% of strains respectively 
(Verhaegh et al., 2008). Although the exact mechanisms of adhesion are as yet 
unknown LOS deficient mutants such as O35E lpxA knockout results in reduced 
adhesion to Chang cells (Spaniol et al., 2008). The main role LOS has in adhesion 
appears to be due to membrane stability and integrity as a disrupted membrane affects 





1.6.2 Trimeric autotransporters 
Trimeric autotransporter (TAA) proteins are virulence factors embedded in the outer 
membrane of some gram-negative bacteria (Cotter, Surana and St. Geme, 2005). 
They are part of the type V secretion system and have a unique tripartite structure 
consisting of an anchor, stalk and head region (Linke et al., 2006). Whilst there are 
some variations between different types of TAAs they all possess a left-handed beta 
roll anchor at the C terminus (Szczesny and Lupas, 2008). This region serves the dual 
purpose of translocating the stalk region and anchoring the protein complex to the 
outer membrane, essentially functioning as a porin within the outer membrane (Mikula 
et al., 2011). The general structure of the stalk domain is reminiscent of a rope, it is 
formed from alpha helical coiled coils (Linke et al., 2006). This region extends the head 
region away from the bacterial cell surface allowing it to make contact with the host 
extracellular matrix. There are various head domain configurations, the most common 
of which is the YadA-like head (Nummelin et al., 2004). It is a nine coiled left-handed 
beta roll comprised of trimeric single strand, left-handed beta-helices. This region 
functions as an adhesin and usually interacts with ECM components as well as 
mediating autoagglutination. Moraxella catarrhalis has 2 main types of TAAs MID/Hag 
and the UspA proteins (de Vries et al., 2009). 
1.6.2.1 MID/Hag  
MID/Hag is a multifunctional trimeric autotransporter protein primarily involved in the 
binding to soluble IgD as well as acting as a B-lymphocyte mitogen, stimulating the 
production of IgD bearing B cells (Forsgren et al., 2001). MID/Hag has the classic 




barrel translocator C-terminus. The N-terminal head domain mediates adherence to 
host receptors as well as IgD binding and hemagglutination (Pearson et al., 2002). 
 
1.6.2.2 UspA proteins 
UspA are also trimeric autotransporters and although they have the general head-
stalk-anchor configuration there are some notable differences. Whilst the anchor 
region has the same left- hand beta roll as other TAAs the head and stalk regions are 
distinct. The N-terminal head domain of the UspA proteins is a left-handed beta 
propeller structure, comprised a series of repeating residues (Hoiczyk, 2000). As with 
all TAAs the stalk region of UspA is comprised of alpha helical coiled coils, unlike the 
right-hand coiled YadA stalk the UspA stalk is an extended left-handed coiled coil 
which at 600-700A is approximately 400-500 angstroms longer than the YadA stalk 
(Agnew et al., 2011) (Conners et al., 2008) (Hoiczyk, 2000) [figure 2]. The Moraxella 
catarrhalis genome encodes for 2 distinct ubiquitous surface proteins; UspA1 and 
UspA2. Purified samples of these proteins are easily identified from one another via 
SDS-PAGE gel. Exposure to the heat and chaotropic agents required for SDS-PAGE 
gel separation causes UspA1 to dissociate resulting in a 100kDa monomeric protein 
(McMichael, Fiske and Fredenburg, 1998). This denaturation does not affect the 
CEACAM binding properties of UspA1 which indicates that the region responsible for 








Figure 2 Trimeric autotransporters 
Diagram comparing a full-length oligomer of a general Trimeric Autotransporter and an UspA1 
monomer. This diagram highlights the disparty in length of the UspA1 stalk compaired to a standard 
trimeric autotransporter as well as the overall structure of both proteins.  









UspA1 was the first of these proteins to be identified and functions mainly as an 
adhesin; binding fibronectin and laminin as well as carcinoembryonic antigen-related 
cell adhesion molecule 1 (CC1) (Hill and Virji, 2003) (Hill et al., 2005). Although it is 
mainly involved in host invasion UspA1 also targets complement related factors such 
as C3 and C4 binding protein. Whilst interactions with fibronectin and laminin are 
carried out by the head region, the CEACAM binding domain of UspA1 is found in the 
stalk. The CC1 binding domain was first identified in the MX2 strain of Moraxella 
catarrhalis and is located 400A from the tip of N terminus head in a region termed rD-
7 (Hill et al., 2005). The CC1 binding properties of the UspA1 rD-7 region are heat 
stable indicating that the binding event is due to a specific amino acid sequence and 
not a folded conformation. This rD-7 region encompasses residues 527-655 and the 
CC1 binding motif is found within amino acids 578–597 (Conners et al., 2008).  
  
UspA1 proteins are densely packed on the surface of Moraxella catarrhalis cells in a 
lollipop forest fashion which could make reaching the CC1 binding site difficult (Agnew 
et al., 2011). UspA1 proteins overcome this problem by introducing a weakness in the 
coiled coil stalk within the rD-7 region which allows it to bend in a boomerang like 
fashion making the binding site much more accessible to the receptor (Conners et al., 
2008) [figure 3]. This flexing of the stalk is due to the interruption of the hydrophobic 
internal residues by polar histidine located at residues 573, 584 and 629 (Conners et 
al., 2008). Although it is a trimeric oligomer, only two out of the three UspA1 proteins 
bind to CC1 molecules. This is due to the 30-60° bend in the stalk which blocks the 






Figure 3 Schematic of UspA1 interaction with CC1.   
This image shows the 30-60 degree bending of UspA1 to expose the CC1 binding rD-7 region, located 










Although UspA2 shares a structural identity of approximately 43% with UspA1 it does 
not share the CEACAM binding properties as it lacks the rD-7 region (Hill and Virji, 
2003). UspA2 is predominantly involved with host immune evasion, preventing 
clearance of the bacteria via the complement cascade. UspA2 avoids complement 
mediated killing by binding a range of complement factors involved in the classical 
pathway including C3, C4bp and vitronectin (Nordström et al., 2004). The binding of 
vitronectin is a key determinant in whether a strain will be serum sensitive or serum 
resistant, this is because binding vitronectin interferes with the polymerisation of C9 
which prevents the formation of the membrane attack complex (Attia et al., 2006). 
Whilst both UspA proteins differ greatly, sequencing of the 035E genome has identified 
a 140 amino acid region of commonality where both genes are 93% identical 
(Lafontaine et al., 2000).  
  
1.6.2.2.3 UspA2H/V 
The novel UspA proteins UspA2H and UspA2V have arisen either through inter- or 
intra- genetic homologous recombination (Hill, Whittles and Virji, 2012). The hybrid 
proteins have properties which can be attributed to both UspA1 and UspA2. UspA2H 
was the first of these novel adhesins to be discovered, its N-terminal identical to UspA1 
whilst its C-terminal is derived from UspA2 (Hill and Virji, 2003) (Lafontaine et al., 
2000). Due to the UspA1 head domain A2H can function as an adhesin. Recent 
studies have shown that approximately 20% of Moraxella catarrhalis strains possess 





UspA2V is the second variant to be discovered, it can bind both CC1 and vitronectin 
(Hill, Whittles and Virji, 2012). All strains which possess the UspA2V protein belong to 
the serosensitive group and 16s ribosomal sequencing data places them in 2/ 3 
phylogenetic group (Blakeway et al., 2017). The 2/3 group does not normally interact 
with CC1 and is the older of the two major evolutionary groups of M. catarrhalis, thus 
UspA2V may actually represent an intermediate evolutionary step (Earl et al., 2016) 
(Blakeway et al., 2017).  
UspA2H and UspA2V may only be the first of these novel hybrid proteins to be 
discovered and more research is needed to assess the possibility of other 
combinations. These homologous recombination events have been observed and 
encouraged experimentally, whereby UspA2V was generated via the inter-strain 
recombination of MX2s UspA1 gene and the genome of the rD-7 negative strain 035E 
(Hill, Whittles and Virji, 2012). This observation has important implications for the 
treatment of Moraxella catarrhalis as selective pressure may encourage the 
recombination events resulting in more virulent proteins which can function as both 







1.7.1 Carcinoembryonic antigen family 
Carcinoembryonic antigen molecules (CEA) are human glycoproteins which belong to 
the immunoglobulin superfamily. They were first discovered in the bile ducts of the 
liver and are often referred to as biliary glycoproteins. The CEA family encodes for 18 
genes and 11 pseudogenes, which are found in a 1.2MB cluster on the long arm of 
chromosome 19 (Hammarström, 1999).  
There are 2 subgroups of the carcinoembryonic antigen family: carcinoembryonic 
antigen related cell adhesion molecules (CEACAM) and pregnancy specific 
glycoproteins (PSG). CEACAMs are involved in cell adhesion and the PSGs are 
immunomodulators which protect the foetus during development (Lisboa et al., 2010) 
(Hammarström, 1999).  
The CEACAM proteins are cell-cell adhesion molecules and can be detected on a 
range of cell types including epithelia, endothelial and leukocytes (Hammarström, 
1999). CEACAM interactions are involved in many cellular processes including but not 
limited to; angiogenesis, differentiation, apoptosis and the modulation of immune 
responses (Tchoupa, Schuhmacher and Hauck, 2014) (Wagener and Ergün, 2000). 
Cell adhesion mediated by CEACAMs can be either a homophilic reaction, via 
CEACAM-Fc fusion protein, or a heterophilic reaction utilizing a CEACAM binding 
ligand such as UspA1 (Gray-Owen and Blumberg, 2006). Homophilic interactions are 
common between human cells whereas heterophilic reactions are usually between 






CC1 originally called CD66a was the first of the CEACAM proteins to be discovered. 
It is primarily found on the apical surface of epithelial cells in the bile ducts, and the 
upper and lower respiratory tracts (GeneCards, 2019). 
Each member of the CEACAM family has the same basic structure; an N-terminal 
immunoglobulin variable-region-like (IgV-like) domain, a variable number of 
immunoglobulin constant-region-type-2-like (IgC2-like) domains and a 
transmembrane anchor region (Villullas et al., 2007). The proteins are also heavily 
glycosylated, constituting over half of the proteins molecular weight (GeneCards, 
2019) (Nagy and Senis, 2019). 
 
There are 11 different isoforms of CC1 which are produced via the alternative splicing 
of the 9 exon regions of the CC1 gene (GeneCards, 2019) [figure 4]. These isoforms 
differ extracellularly in the number of their IgC2-like domains and the level of 
glycosylation. With regards to the cytoplasmic domains there are 4 main variables that 
may arise; either a long or short cytoplasmic tail, a unique C-terminus which indicates 
that the protein will be secreted or an Alu repeat sequence in the open reading frame 
(Gray-Owen and Blumberg, 2006). The intercellular binding and the intracellular 
signalling properties of the isoforms vary depending on which immunoglobulin-region-







Figure 4 Isoforms of Human CC1. 
 
Isoforms are generated via alternative splicing of CC1 transcripts in order to vary in the number of IgC2 
domains and cytoplasmic tails. The heavy glycosaltion of the protiens is also evident, this results in CC1 
appearing to have a much higher molecular weight when examined via SDS-Page gel.  
Key: Amino-terminal IgV-like domain (purple circle). IgC2-like domain (red/orange circle). N-linked 










1.7.2.1 CC1 and infection  
The ubiquitous presence of CC1 on respiratory epithelial cells makes it an ideal target 
for pathogenic bacteria (Hill et al., 2005) (Tchoupa, Schuhmacher and Hauck, 2014). 
It is an important receptor for many bacterial adhesins such as the UspA1 protein of 
Moraxella catarrhalis as well as the OPA proteins of Neisseria (Hill et al., 2005) (Martin 
et al., 2016). As well as acting as a pathway to colonise host cells, CC1 binding has 
also been found to inhibit immune-cell function thus suppressing specific immune 
responses to infection (Gray-Owen and Blumberg, 2006).  
During a Moraxella catarrhalis infection the CC1 binding ligand UspA1 flexes in the 
stalk region exposing the specific CC1 binding motif, the so called rD-7 region 
(Conners et al., 2008) (Hill et al., 2005). This region is a sequence specific receptor 
for CC1 meaning that even after denaturing it is still capable of binding CC1. Although 
UspA1 is a trimeric oligomer and each of the monomers has an rD-7 region it only 
binds two molecules of CC1 at a time, this is due to the bending of the UspA1 stalk. 
This conformational change results in two rD-7 regions being fully exposed for CC1 
interactions whilst the third is inaccessible to the receptor site (Conners et al., 2008). 
In contrast to the heat stable interactions between UspA1 and CC1, the OPA proteins 
of Neisseria and OMP P1 of Haemophilus influenza are labile. CC1 binding by OPA 
and OMP P1 is a structure dependant event (Tchoupa et al., 2015) (Martin et al., 
2016). The 3-dimensional structure that the proteins form when folded brings 
otherwise physically distant motifs into proximity which together act as a ligand for 






Screening of Moraxella catarrhalis isolates for CC1 binding activity revealed that the 
strain dubbed MX13L, a derivative of the parent strain ATCC25240, adhered to CC1. 
This is unexpected as this strain lacks expression of both UspA1 and UspA2. Further 
investigations confirmed that MX13L did not possess a functional rD-7 region, as anti-
rD-7 antibodies did not bind to this strain.  
Although SDS-Page gels and Western blots did not reveal any CC1 binding activity, 
dot blots of MX13L continued to demonstrate binding. This heat lability indicated that 
the novel ligand relied on a 3-dimensional structure to bind CEACAM. All other labile 
CC1 adhesins have a beta barrel structure, such as the Neisseria OPA proteins or the 
OMP P1 of Haemophilus influenza (Tchoupa et al., 2015) (Martin et al., 2016). This 
project aims to identify the novel CC1 binding ligand found in MX13L. 
 Value 
In the last few decades, Moraxella catarrhalis has established itself as an important 
pathogen of the upper and lower respiratory tracts, along with rising incidences of 
sepsis (Verduin et al., 2002). It is a serious cause of morbidity and a drain on the 
healthcare system. Although antibiotic resistance is widespread in the Moraxella 
catarrhalis population with beta lactamases being obsolete and resistance to second 
generation cephalosporins rising, there is currently no vaccine (Shi et al., 2018) (Khan 
et al., 2009). Identifying a new CC1 binding ligand will not only provide a greater 
understanding of the pathogenicity of Moraxella catarrhalis but it may also provide a 




  Structure 
Due to the labile nature of the ligand we were unable to identify the molecular weight 
of this protein. Instead the first step in investigating the adhesin was to create a target 
list using bioinformatic techniques. As all other examples of labile ligands are beta 
barrel structures a list of the beta barrel outer membrane proteins (BOMPs) found in 
ATCC25240 needed to be generated. Once a target list was obtained molecular 
biology techniques were employed. This included generating primers to the target 
BOMPs, with the aim of expressing the proteins in E. coli and performing adhesion 
assays on CC1 expressing HeLa cells. A transposon library was also generated in 
order to knockout the CC1 binding gene, confirming the results of the adhesion 
assays.  
 Objectives 
This project aims to identify the novel CC1 binding ligand found in MX13L by: 
• Creating a target list of potential beta barrel outer membrane proteins found in 
strain ATCC25240 using bioinformatic techniques  
• Expressing all target proteins in E.coli via ligation independent cloning 
• Assessing the CC1 adhesive properties of target proteins via adhesion assays 
• Using the ez tn5 transposon to generate a transposon library in order to 
generate random genetic knock outs of Mx13L 
• Identifying which randomly generated mutants of Mx13L did not bind to CC1 
via dot blots  





3 METHODS  
 Cell strains and growth conditions 
3.1.1 Bacterial strains and growth conditions  
Moraxella catarrhalis strains were grown either on heart brain infusion (BHI) agar or in 
heart brain infusion broth, both were supplemented with 10% (v/v) heated Horse blood. 
For transposon work HBHI plates were also supplemented with 50 μg∙mL-1 kanamycin 
(Kan).  
E. coli strains were grown either on Lysogeny Broth (LB) agar or broth, as E. coli were 
used to produce recombinant proteins the plates/ broth were often supplemented with 
antibiotics and compounds. Ampicillin (Amp) at a concentration of 100 μg∙mL-1 as well 
as 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 20 μg∙mL-1 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-Gal) were used in screening and inducing 
the production of prokaryotic recombinant proteins. Zeocin™ (Zeo) at a concentration 
of 100 μg∙mL-1 replaced the ampicillin when inducing the production of eukaryotic 
proteins in XL10-Gold cells.  
Both Moraxella catarrhalis strains and E. coli strains were grown for approximately 12-
16 hours overnight at 37 °C in a 5% CO2 incubator. Both static and shaking conditions 
were used for liquid cultures, shaking occurred at 200 RPM.  
Stocks of bacteria were stored at -80 °C in the appropriate growth medium (LB broth 





3.1.2 Eukaryotic strains and growth conditions  
All cells were grown in a forced air incubator at 37 °C with 5 % CO2. HeLa cell lines 
used were grown in Roswell Park Memorial Institute medium 1640 (RPMI1640), whilst 
CHO cells were grown in Ham′s Nutrient Mixture F12. Both growth media were 
supplemented with 100 μg. mL-1 penicillin (Pen); 100 μg.mL-1 streptomycin (Strep); 
300 μg.mL-1 L-glutamine; and 10 % (v/v) foetal bovine serum (FBS). When low serum, 
< 5 % (v/v) FBS, or serum free conditions were required, FBS was replaced with 
Gibco® Insulin-Transferrin-Selenium (ITSG) media supplement. 
Prior to use in experiments cells were passaged a minimum of three times to ensure 
proper growth and absence of any visible contamination. When cells reached ~80% 
confluency they were passaged via tryptic digestion. Growth media was discarded 
from the flask and cells were washed with 5 mL of Dulbecco’s phosphate buffered 
saline (DPBS) to remove any residual traces of FBS. The DPBS was aspirated and 
cells were incubated at 37°C for 5 minutes with 5 mL of 0.25% trypsin-EDTA 
(2.5x103 μg.mL-1 Trypsin and 200 μg.mL-1 of EDTA) (Ethylenediaminetetraacetic 
acid). Once cells had detached 5 mL of the appropriate media was added in order to 
neutralise the protease activity of trypsin. Cells were then centrifuged at 300 g for 5 
minutes. Residual media was discarded, and the pellet resuspended in growth media. 
Cells were then reseeded into a vent cap cell culture flask containing the appropriate 





3.1.3 Freezing eukaryotic cells 
To store eukaryotic cells long term the cells were kept in liquid nitrogen below -135 °C. 
In preparation for storage, cells were passaged via tryptic digestion as normal. The 
growth media was discarded from the flask and 5 mL of DPBS was washed over the 
cell. After the DPBS was removed, cells were incubated at 37 °C for 5 minutes with 
5 mL of 0.25% trypsin-EDTA. When 80-100% of the cells had detached from the flask 
surface 5ml of growth media was added to neutralise the trypsin activity. Cells were 
then centrifuged at 300 g for 5 minutes. Residual media was discarded, and the pellet 
resuspended in freezing media which consisted of 90% FBS + 10% DMSO (Dimethyl 
sulfoxide). Working quickly the resuspended cells were aliquoted into cryovials before 
being placed into a controlled freezing container which submerged the cells in 
isopropanol. This freezing chamber was then placed into a -80 °C freezer overnight 
whereby the container cooled the cells at a rate of -1 °C per minute. The next day cells 
were removed from the freezing chamber and deposited into liquid nitrogen for long 
term storage. 
 
 Producing recombinant CC1-Fc 
3.2.1 Creating a stable CC1-Fc secreting cell line 
3.2.1.1 Selecting a plasmid 
To produce recombinant soluble CC1-Fc proteins, the gene encoding residues for 
extracellular protein, were cloned into pINFUSE-hIgG2-Fc2 using ligation independent 




enhances the levels of eukaryotic gene expressions. pINFUSE-hIgG2-Fc2 is a cloning 
plasmid specifically designed to generate a secreted Fc-fusion protein. To accomplish 
this the plasmid expresses the CH2 and CH3 domains, of the Fc region, of human 
IgG2 heavy chain, as well as the hinge region. In addition to this pINFUSE-hIgG2-
Fc2 also encodes the IL2 signal sequence allowing Fc-Fusion proteins to be 
generated from proteins that are not naturally secreted.  
 
3.2.1.2 Amplifying CC1-Fc 
CC1-Fc encoding DNA was amplified using polymerase chain reaction (PCR) using 
primers (appendix 1) designed to amplify the shorter isoform from extracted full length 
CC1-4L DNA. The primers also contained 5’ DNA regions homologous to linear 
pINFUSE-hIgG2-Fc2 in order to facilitate ligation independent cloning. PCR mix was 
as follows: 7 μL nuclease free water (ddH2O), 0.5 μM of forward and reverse primers, 
as well as 1 ng.μL-1 genomic DNA were added to 10 μL CloneAmp™ high fidelity PCR 
premix in a 0.2 mL PCR tube. PCR was performed under the following conditions: 
initial denaturing 95 °C 5 min; followed by 30 cycles of: 95 °C 15 sec, 60 °C 15 sec, 
72 °C 5 sec/kbase DNA; finished by 72 °C 10 min for the final extension. 
 
3.2.1.3 XL10-Gold cell transformation  
The pINFUSE-hIgG2-Fc2 plasmid was linearized via digestion at 37 °C for 1 hr by the 
restriction enzymes BglII-HF® and EcoRV-HF®. The linearized plasmid was then 




instructions in order to remove the restriction enzymes. After purification a 0.8% 
agarose gel comparing the linearized plasmid and uncut plasmid was run at 200 V for 
1 hour in order to ensure that the plasmid had been fully linearized.  
A 2:1 molar ratio of amplified CC1-Fc and linear pINFUSE-hIgG2-Fc2 were incubated 
together at 50 °C for 15 min with 1X In-Fusion® master mix. This reaction mix was 
then incubated on ice for 30 min with chemically competent XL10-Gold ultracompetent 
cells. In order to induce the uptake of the vector the cells were heat-shocked by 
incubation at 42 °C for 40 secs followed by 5 min on ice. SOC medium (Super Optimal 
broth with Catabolite repression) preheated to 37 °C was added to promote the 
recovery of the XL10-Gold ultracompetent cells as well as boost the uptake of plasmid. 
Following a recovery period of 1 hour in a shaking incubator at 200 RPM and 37 °C, 
transformed cells were streaked onto selection plates (see section 3.1.1) and 
incubated overnight at 37 °C.  
As pINFUSE-hIgG2-Fc2 did not contain a lac operon blue white screening was not 
possible, thus individual colonies were picked at random and grown in 10 mL of 
selection LB broth overnight in the shaking incubator with the previously described 
conditions. Plasmid DNA was extracted via a QIAprep® Spin kit and the concentration 
of the plasmid was adjusted to 100 ng∙μL-1 using a UV-Vis spectrophotometer. PCR 
was used to confirm successful transformation using the same method described 
above.  
3.2.1.4 Kill curve  
Prior to transfection with CC1-Fc DNA a kill curve was undertaken to determine the 




untransfected CHO cells. Cells were seeded in a 24 well tissue culture plate with F-12 
Ham media and allowed to grow until 80% confluency. Media was then aspirated and 
replaced with F-12 Ham supplemented with zeocin at concentrations ranging from 
1000 μg∙mL-1 to 0 μg∙mL-1. For 10 days the wells were examined daily, and the media 
replaced every 2 days to ensure that the concentration of antibiotic remained constant. 
After 10 days the minimum Zeocin concentration required to kill all cells was 
determined.  
 
3.2.1.5 Transfecting CHO cells  
Prior to transfection pINFUSE-hIgG2-Fc2-CC1-Fc DNA was linearized via digestion 
with NotI restriction enzyme using the same method as previously described (see 
section 3.2.3). Linear plasmids integrate better into eukaryotic genomes for stable 
transfection.  
CHO cells were grown in 24 well tissue culture plates to 70-90% confluency. The cells 
were washed with 15 mL of Dulbecco’s phosphate buffered saline (DPBS) to remove 
excess serum. Lipofectamine® 3000 transfection mixture was prepared in 2 tubes. In 
the first tube 36 μL lipofectamine 3000 reagent was diluted with 600 μL Opti MEM 
medium. The second tube mixed 24 μL of linearized pINFUSE-hIgG2-Fc2-CC1-Fc 
DNA with 48 μL of P3000 reagent and diluted this mixture with 1200 μL of Opti-MEM. 
After mixing the contents of the tubes in a 1:1 ratio, the Lipofectamine® 3000 
transfection mixture was incubated for 15 min at room temperature. This incubation 
time allowed lipid complexes to form around the plasmid which ensured that the target 




Lipofectamine® 3000 transfection mixture per well and incubated for 24 hours at 37°C. 
After 24 hours 500 μL of Ham′s Nutrient Mixture F12 additionally supplemented with 
400 μg.mL-1 of Zeocin (as determined by kill curve) was added to each well.  
 
3.2.1.6 Determining CC1-Fc production post-transfection  
In order to determine that transfected cells were successfully producing the 
recombinant protein the supernatant was collected and tested. A sample of 
supernatant was collected subjected to serial dilution with fresh media. 50 μL aliquots 
were transferred to a nitrocellulose membrane via direct pipetting and vacuum drying. 
Nitrocellulose was submerged in 3% (w/v) bovine serum albumin (BSA; diluted in PBS-
T), for 1hr at room temperature, in order to block non-specific binding sites. 3% BSA 
was then aspirated and the nitrocellulose strip overlaid with A0115 diluted from stock 
solutions to 1 μg.mL-1 in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 at RT for 1 
hour. The membrane was then washed 3 times with PBS-T and the final wash was 
incubated for 5 min before being aspirated. The secondary antibody applied was anti-
rabbit-Fc conjugated to alkaline phosphatase diluted to 1 μg.mL-1 in 1% (w/v) BSA in 
PBS-T with 0.05% (w/v) NaN3 at RT for 1 hour. The wash step was repeated as before. 
The blot was developed for 15 mins using 6.6 μL∙mL-1 of NBT and 3.3 μL∙mL-1 of BCIP 






3.2.1.7 Monoclonal cell line selection  
The wells which resulted in positive supernatants underwent tryptic digestion; half of 
the cells were reseeded into a T-175 tissue culture flask to maintain a polyclonal 
population. The other half of the CC1-Fc transfected CHO cells were seeded into a 96 
well tissue culture plate via limiting dilution, in order to select a monoclonal population. 
Both sets of cells were maintained in Ham′s Nutrient Mixture F12 containing 
400 μg.mL-1 of zeocin.  
Cells undergoing monoclonal selection had their growth media replaced every 48 
hours. After 11 days under selection pressure any monoclonal populations evident 
were identified, and their populations expanded via growth in separate T-75 tissue 
culture flasks.  
 
3.2.1.8 Determining the production of CC1-Fc in monoclonal populations 
In order to ensure that the selected monoclonal populations were producing CC1-Fc, 
50 μL aliquots of supernatant from each population, were transferred to a nitrocellulose 
membrane. Nitrocellulose was submerged in 3% (w/v) BSA, diluted in PBS-T, for 1 
hour at room temperature, to block non-specific binding sites. The BSA was removed 
and the nitrocellulose strip was then overlaid with A0115 diluted from stock solutions 
to 1 μg.mL-1 in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 at RT for 1 hour. The 
membrane was washed 3 times with PBS-T and the final wash was incubated for 5 
min before being aspirated. The secondary antibody was applied at RT for 1 hour; 
anti-rabbit-Fc conjugated to alkaline phosphatase diluted to 1 μg.mL-1 in 1% (w/v) BSA 




were developed for 15 mins using 6.6 μL∙mL-1 of NBT and 3.3 μL∙mL-1 of BCIP in AP 
buffer.  
 
3.2.1.9 Protein Purification  
The supernatants collected from both monoclonal and polyclonal populations were 
pooled and filtered through a 0.2 μm syringe filter to remove any cell debris. Prior to 
protein purification a gravity flow column containing 1 mL Protein A-Sepharose® resin 
was equilibrated by washing 15 column volumes (CV) of protein A loading buffer 
through the column. The supernatant was then mixed with Protein A Loading Buffer in 
a 1:1 ratio before being added to the column and allowed to flow through under gravity. 
A further 15 CV of loading buffer were passed through the column to ensure any 
unbound proteins were removed. 3 CV of elution buffer were passed through the 
column, and fractions were collected and immediately neutralised with Protein A 
Neutralisation Buffer. The collected fractions were purified via dialysis; fractions were 
loaded into dialysis tubing membrane 5000 kDa MWCO and placed into 5 L of dialysis 
buffer. Dialysis occurred overnight and the buffer was changed 3 times with the last 
change left overnight. The total volume was concentrated using Vivaspin® 20 spin 
columns and final concentration was determined via the Pierce™ BCA Protein Assay 






3.2.2 Determining the fidelity of CC1-Fc  
3.2.2.1 Dot Blot 
To compare the interactions of the new recombinant CC1-Fc to a previously 
purchased laboratory stock of CC1-Fc (oCC1-Fc), 50 μL of Moraxella catarrhalis 
isolates grown to OD280 0.5 were transferred to nitrocellulose membrane via direct 
pipetting and vacuum drying. The non-specific binding sites were blocked for 1 hour 
at room temperature via 3% (w/v) bovine serum albumin (BSA; diluted in PBS-T). One 
membrane was overlaid with the recombinant CC1-Fc produced by the transfected 
CHO cells and the other with stock oCC1-Fc both diluted to 0.2 μg∙mL-1 in 1% BSA-
PBST. The membranes were washed twice with PBS-T, the third wash was incubated 
for 5 min for before being decanted. Anti-human-Fc conjugated to alkaline 
phosphatase diluted to 1 μg.mL-1 in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 
was added to each strip and incubated for 1 hour at room temperature. The blots were 
washed as before and developed for 15 mins using developing buffer (6.6 μL∙mL-1 of 
NBT and 3.3 μL∙mL-1 of BCIP in AP buffer).  
 
3.2.2.2 SDS-Page gel & Western blot 
To ensure that the recombinant protein produced was identical in function to oCC1-Fc 
it was necessary compare the size and functionality of CC1-Fc. A 7.5% resolving gel 
and a 5% stacking gel were prepared. The resolving gel consisted of 4.9 mL dH2O, 
2.5 mL Tris hydrochloride (Tris HCl) pH 8.8, 100 μL 10% sodium dodecyl sulphate 
(SDS) 2.5 mL acrylamide. Whilst the stacking gel was made using 3.05 mL of dH2O, 




pouring 50 μL 10% ammonium persulfate (APS) and 10 μL Tetramethyl 
ethylenediamine (TEMED) were added to the resolving gel whilst half that amount was 
added to the stacking gel. The resolving gel was poured and set before the stacking 
gel was layered on top. Once both gels had set, CC1-Fc and oCC1-Fc were 
standardised to 0.2 μg∙mL-1 and boiled with to 20 μL Laemmli buffer at 95 °C for 5 
mins. 10 μL of denatured samples were then loaded into each well. Gels were run in 
1x SDS running buffer for 1.5 hours at 200 V.  
One gel was stained with Coomassie in order to visualise the protein size, whilst the 
other was transferred onto nitrocellulose membrane via a wet transfer. To transfer the 
gel onto a nitrocellulose membrane both the gel and membrane were equilibrated in 
transfer buffer before being sandwiched together in a filter paper-gel-membrane-filter 
paper manner. The ‘transfer sandwich’ was clamped together by a support grid and 
placed into an electro transfer tank filled with transfer buffer for 1 hour at 100 V. A 
cooling block was also placed into the tank to dissipate the heat produced.  
Once the gel had transferred the membrane was blocked with 3% (w/v) bovine serum 
albumin (BSA; diluted in PBS-T) for 1 hour at room temperature. The membrane was 
then incubated with 1 μg.mL-1 A0115 in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 
at for 1 hour at room temperature. The membrane was then washed 3 times with PBS-
T, the final wash included a 5 min incubation period. AP conjugated anti-rabbit 
secondary antibody 1 μg.mL-1 in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 was 
applied to the membrane for 1 hour at room temperature. The washing step was then 
repeated before the membrane was visualised with 6.6 μL∙mL-1 of NBT and 




 Identifying a novel CC1 binding protein  
3.3.1 Assessing MX13L interactions with CC1 
3.3.1.1 Dot blot 
To compare the interactions of different Moraxella catarrhalis strains with CC1-Fc, 
strains of Moraxella catarrhalis (see table) were grown and killed via freeze thaw lysis. 
The samples were standardized to A280 OD 0.5 and 50 μL of each was transferred to 
nitrocellulose membrane via direct pipetting and vacuum drying. Using 3% (w/v) 
bovine serum albumin (BSA; diluted in PBS-T) the non-specific binding sites were 
blocked for 1hr at room temperature. After initial blocking CC1-Fc was diluted to 
0.2 μg∙mL-1 in 1% (w/v) BSA-PBST, this acted as the primary antibody, the membrane 
was soaked in primary antibody for 1 hour at room temperature. The membrane was 
then washed three times with PBS-T, the third wash was incubated for 5 min for before 
being decanted. Anti-human-Fc conjugated to alkaline phosphatase diluted to 
1 μg.mL-1 in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 was added to each strip 
and incubated for 1 hour at room temperature. The blots were washed as before and 
developed for 15 mins using developing buffer (6.6 μL∙mL-1 of NBT and 3.3 μL∙mL-1 of 
BCIP in AP buffer). 
 
3.3.1.2 Amplifying UspA1/ UspA2 proteins 
In order to identify how MX13L was binding to CC1, PCR was performed to amplify 
UspA1 and UspA2 encoding DNA from the MX13L genome using the UspA specific 




primers would amplify UspA2/V/H (Hill, Whittles and Virji, 2012). MX2 and MX1 acted 
as positive controls for this experiment, MX2 encodes for UspA1 whilst MX1 encodes 
for UspA2V. PCR mix was as follows: 7μL nuclease free water (ddH2O), 0.5 μM of 
forward and reverse primers, as well as 1 ng.μL-1 genomic DNA were added to 10 μL 
CloneAmp™ high fidelity PCR premix in a 0.2 mL PCR tube. PCR was performed 
under the following conditions: initial denaturing 95 °C 5 min; followed by 30 cycles of: 
95 °C 15 sec, 55 °C 15 sec, 72 °C 5 sec/kbase DNA; finished by 72 °C 10 min for the 
final extension. 
 
3.3.1.3 Determining rD-7 production 
To ensure that the binding of MX13L to CC1 was not caused by presence of rD-7 
within UspA1 or elsewhere, Moraxella catarrhalis strains; MX13L, MX13D, 
MX13ΔUsp, and MX2 were grown and lysed via freeze thaw lysis to release internal 
proteins. The bacteria lysates and purified rD-7 were standardized to A280 OD 0.5 and 
50 μL of each was transferred to nitrocellulose membrane via direct pipetting and 
vacuum drying. Using 3% (w/v) bovine serum albumin (BSA; diluted in PBS-T) the 
non-specific binding sites were blocked for 1 hour at room temperature. After initial 
block the membrane was overlaid with anti-rD-7 bleed-out diluted 1:100 in 1% (w/v) 
BSA-PBST for 1 hour at room temperature. The membrane was then washed three 
times with PBS-T, the third wash was incubated for 5 min before being decanted. Anti-
rabbit-Fc conjugated to alkaline phosphatase diluted to 1 μg.mL-1 in 1% (w/v) BSA in 
PBS-T with 0.05% (w/v) NaN3 was added to each strip and incubated for 1 hour at 
room temperature. The blots were washed as before and developed for 15 mins using 




3.3.1.4 Western blot 
A western blot was run with Moraxella catarrhalis strains; MX13L, MX13D, 
ATCC25240, and MX2, the OpaLess Neisseria strain was also utilised, to ascertain 
the molecular weight of the novel adhesin. A 7.5% resolving gel; 4.9 mL dH2O, 2.5 mL 
Tris HCl pH 8.8, 100 μL 10% SDS and 2.5 mL acrylamide. A 5% stacking gel was also 
prepared using 3.05 mL of dH2O, 1.25 mL Tris HCl pH 6.8, 50 μL 19% SDS and 
650 μL acrylamide. Before the gels were poured 50 μL 10% APS and 10 μL TEMED 
were added to the resolving gel, whilst 25 μL 10% APS and 5 μL TEMED added to the 
stacking gel. The resolving gel was poured and set before the stacking gel was layered 
on top. Once both gels had set, the samples were boiled in 20 μL laemmli buffer at 95 
°C for 5 mins. 10 μL of denatured samples were then loaded into each well. Gels were 
run in 1x SDS running buffer for 1.5 hours at 200 V.  
To transfer the gel onto a nitrocellulose membrane both the gel and membrane were 
equilibrated in transfer buffer before being sandwiched between filter paper and held 
together by a support grid. The gel/membrane sandwich was then placed into a 
transfer buffer filled tank for 1 hour at 100 V. A cooling block was also placed into the 
tank to dissipate the heat produced.  
Once the gel had transferred the membrane was blocked with 3% (w/v) bovine serum 
albumin (BSA; diluted in PBS-T) for 1 hour at room temperature. The membrane was 
then incubated with 1 μg.mL-1 CC1-Fc in 1% (w/v) BSA in PBS-T with 0.05% (w/v) 
NaN3 at for 1 hour at room temperature. The membrane was then washed 3 times with 
PBS-T, including a 5 min final wash. 1 μg.mL-1 Rabbit-anti-Human-IgG(Fc)-AP 
secondary antibody was applied to the membrane for 1 hour at room temperature. The 




of NBT and 3.3 μL∙mL-1 of BCIP in AP buffer and the membrane left to develop for 15 
minutes.  
 
3.3.2 Identifying target proteins 
3.3.2.1 Bioinformatic analysis 
The whole genome sequence of ATCC25240, parent strain of MX13L, was analysed 
by PSORT, a programme which determines the subcellular localisations of proteins. 
The results of the PSORT analysis was passed onto another programme called BOMP 
which can determine if a protein is likely to be a beta barrel or not.  
3.3.2.2 Amplifying target genes  
In order to express the target BOMP proteins as faithfully to native as possible, stellar 
E. coli cells were transformed with the plasmid pOAF containing individual target 
protein encoding genes. pOAF is a surface expression vector based on the pOPINF 
plasmid; the E. coli OmpA signal peptide is encoded upstream of the pOPINF 5’ add 
on sequence which facilitates surface expression of recombinant proteins on E. coli 
host strains.  
The target genes were amplified via PCR from extracted MX13L DNA using primers 
designed with homologous 5’ DNA overlap regions with linear pOAF (Table1). 7μL 
nuclease free water (ddH2O), 0.5 μM of forward and reverse primers, as well as 1 
ng.μL-1 genomic DNA were added to 10 μL CloneAmp™ high fidelity PCR premix in a 




PCR was performed under the following conditions: initial denaturing 98 °C 5 min; 
followed by 30 cycles of: denaturing 98 °C 10 sec, annealing X °C 15 sec, extension 
72 °C 5 sec∙kBase-1 DNA; finished by 72 °C 5 min for the final extension. The 



















Table 1 Primers designed to bind to outer membrane beta barrel proteins in MX13 
(ATCC25240).  
The accession numbers of each target protein and the corresponding forward and 
reverse primers are listed as well as the required annealing temperature. The pOAF 
overlap sequences indicated at the bottom of the table were added to the 5’ end of 
each primer to ensure that ligation independent cloning was possible. 
Accession 
ID 











































































































3.3.2.3 E. coli transformation  
The plasmid was linearized via digestion at 37 °C for 1 hour by the restriction enzymes 
HindIII-HF® and KpnI-HF®. The linearized plasmid was subsequently purified using 
QIAquick® PCR Purification Kit according to the manufacturer’s instructions in order 
to remove the restriction enzymes.  
The amplified target DNA was purified using the QIAquick PCR Purification Kit and 
cloned into pOAF using ligation independent cloning. Amplified target DNA and linear 
pOAF were incubated together in a 2:1 molar ratio at 50 °C for 15 min with 1X In-
Fusion® master mix. This reaction mix was then incubated on ice for 30 min with 
chemically competent Stellar E. coli cells. Cells were heat-shocked by incubation at 
42 °C for 40 secs followed by 5 min on ice to induce the uptake of cloned plasmids. to 
promote the recovery of the competent cells SOC medium preheated to 37 °C was 
added to the cells. Following a 1 hr recovery period in a 37 °C shaking incubator at 
200 RPM, transformed cells were plated onto LB agar (containing Amp, IPTG and X-
Gal) and incubated overnight at 37 °C.  
Following overnight incubation on selection agar, colonies were selected, and 
transformation was confirmed via PCR as described above. Liquid cultures of 
successful transformations were set up overnight in selection LB broth (containing 
Amp, IPTG and X-Gal) at 37 °C (see 3.1.1 for more info). Glycerol stocks of each 





3.3.2.4 Adhesion assays  
3.3.2.4.1 Eukaryotic cell preparation  
Prior to use in adhesion assay experiments HeLa cells expressing human CC1 and 
HeLa Neo cells that didn’t express any CEACAM were grown to confluence at 37 °C 
in T-75 tissue culture flasks. The cells were passaged via tryptic digestion and 100 μL 
seeded into 96-well plates at a concentration of approximately 2x104 cells per well. 
After 48 hrs cells had reached confluency and the media was replaced with Medium 
199 (devoid of any antibiotics) pre-warmed to 37 °C. 
 
3.3.2.4.2 Bacterial preparation  
Prior to use in adhesion assay experiments stellar E. coli transformed to surface 
express target proteins were grown overnight at 37 °C in LB broth supplemented with 
1 mM IPTG and 100 μg.mL-1 of AMP. The cultures were diluted to A260 OD 1.0 in 
pre-warmed Medium 199 (devoid of any antibiotics), this optical density corresponded 
to an estimated multiplicity of infection (MOI) of 100 bacterial cells per 1 eukaryotic 
cell. Stellar E. coli expressing pOAF only, were also grown to the same conditions, 
these cells acted as a negative control.  
 
3.3.2.4.3 Infection and cell fixation  
The media was removed from the eukaryotic cells, washed in antibiotic free media to 
remove antibiotics prior to bacterial overlay. 100 μL bacterial suspensions containing 




at 37 °C for 3 hours. After incubation the wells were thoroughly washed with Medium 
199 to remove unbound bacteria and then washed twice more with warm DPBS to 
remove any traces of media. Prior to the addition of a fixing agent all liquid was 
completely removed from the wells. To fix the cells 50 μL of 4% (w/v) 
paraformaldehyde (PFA; dissolved in PBS) was added to each well and the plates 
were incubated overnight at 4 °C.  
 
3.3.2.4.4 Cell staining  
In order to prevent interference prior to staining PFA was removed and wells were 
washed with DPBS containing 0.05% [w/v] Sodium Azide, which was then discarded. 
To prevent non-specific antibody binding 100 μL of 3% (w/v) BSA was added to each 
well and the plates were incubated for 1 hour at room temperature on a rocker. The 
BSA was removed and 100 μL of the primary antibody was applied; 1 μg.mL-1 of 
mouse anti-E. coli LPS in 1% (w/v) BSA in PBS-T. Cells were again incubated for 1 
hour at room temperature on a rocker. The primary antibody was aspirated, and wells 
were washed 3 times with PBS-T, the third wash included a 5 min incubation time to 
ensure any antibody residue was removed. 100 μL of fluorescent secondary antibody 
diluted to 1 μg.mL-1 in 1% (w/v) BSA in PBS-T was added to each well and incubated 
for 1 hour at room temperature. The secondary antibody was Goat anti-Mouse Alexa 
488. Following the removal of the secondary antibody the washing step was repeated 
as above. 100 μL of 1 μg.mL-1, 4',6-diamidino-2-phenylindole (DAPI) in 1% (w/v) BSA 
in PBS-T was added to each well and incubated for 15 mins a room temperature. The 
washing step was repeated as above, to remove excess DAPI. 50 μL of PBS-Azide 




3.3.2.4.5 Cell imaging 
Wells were viewed under a fluorescent microscope (Olympus IX70) using excitation 
wavelengths set at 360 nm and 485 nm to detect DAPI and Alexa 488 respectively. 
Images representative of the cells in each well were captured using a Hamamatsu 
C4247-95 ORCA 100 series camera and analysed with HCImage. HeLa cell nuclei 
fluoresced blue due to the DAPI stain whilst the bacteria fluoresced green.  
3.3.2.4.6 Dot blot 
Transformed E. coli strains which displayed an increasing in binding to HeLa CC1 cells 
were grown overnight and lysed. The samples were standardized to A280 OD 0.5 and 
50 μL of each was transferred to nitrocellulose membrane via direct pipetting and 
vacuum drying. Using 3% (w/v) BSA (diluted in PBS-T) the non-specific binding sites 
were blocked for 1 hour at room temperature. After initial blocking CC1-Fc was diluted 
to 0.2 μg∙mL-1 in 1% (w/v) BSA-PBST for 1 hour at room temperature. The membrane 
was then washed three times with PBS-T, the third wash was incubated for 5 min for 
before being decanted. 1 μg.mL-1 Rabbit-anti-Human-IgG(Fc)-AP 1% (w/v) BSA in 
PBS-T was added to each strip and incubated for 1 hour at room temperature. The 
blots were washed as before and developed for 15 mins using developing buffer (6.6 






3.3.3 Transposon library  
3.3.3.1 Preparing electrocompetent cells 
In order to induce uptake of the EZ-Tn5™ <KAN-2>Tnp Transposome™ via 
electroporation it was necessary to prepare electrocompetent Moraxella catarrhalis 
cells (Holm, Vanlerberg, Sledjeski and Lafontaine, 2003). A falcon tube containing 5 
mL HBHI broth was inoculated with MX13L from a fresh HBHI plate and placed in a 
250 RPM shaking incubator for 12 hours at 37 °C. the next day 1ml of liquid culture 
was reinoculated into 50 mL of HBHI broth and grown in a shaking incubator under 
the same conditions as before. Once the culture reached an OD600 0.6 it was placed 
on ice for 15 mins, from this point onwards the culture was kept ice cold. The culture 
was then divided into 4 sterile, chilled falcon tubes and centrifuged for 10 mins at 5000 
RPM. The supernatant was decanted, and the pellet resuspended in ice cold 10% 
glycerol bringing the volume up to 50 mL before being spun as previously. This step 
of spinning and resuspension with glycerol was performed a further 3 times. The final 
resuspension of cells was performed using the residual glycerol after the supernatant 
was discarded (approximately 2 mL). 50 μL of the now electrocompetent cells were 
used for immediate electroporation whilst the rest were reserved in 100 μL aliquots 
and stored at -80 °C.  
 
3.3.3.2 Electroporation of Moraxella catarrhalis with transposon  
Prior to electroporation a reaction mixture consisting of 50 μL aliquot of 
electrocompetent cells along with 1 μL of the EZ-Tn5™ <KAN-2>Tnp Transposome™ 




reaction mixture was incubated at room temperature for 30 mins before being 
transferred to a 0.2 cm electroporation cuvette. The electroporation cuvette was 
inserted into the Genepulser apparatus chamber between the contacts for the 
electrodes. The electrocompetent Moraxella catarrhalis cells were transformed with 
the transposon via a single pulse using the settings 2.5 kV, 25 μF, and 200 Ω 
(Nordström, Blom, Forsgren and Riesbeck, 2004). The cuvette was immediately 
removed from the apparatus and 947 μL of SOC medium was added to the cuvette, 
before the total volume was transferred to a microcentrifuge tube and incubated for 1 
hour at 37 °C to facilitate recovery and cell growth. After the recovery time had elapsed 
the 100 μL aliquots of the cell mixture were plated on 10 HBHI plates supplemented 
with 25 μg∙mL-1 of kanamycin. The plates were grown overnight at 37 °C in a 5% CO2 
incubator. 
 
3.3.3.3 Transposon library screening  
In order to analyse the CC1-FC binding capabilities of the Moraxella catarrhalis 
transformed with the transposon, a selection of individual colonies was picked from 
the surface of the HBHI Kan supplemented plates, using sterile toothpicks. The point 
of a sterile toothpick was used to transfer a single colony from the HBHI plate into the 
well of a 96 well tissue culture plate containing 300 μL of HBHI supplemented with 
25 μg.mL-1 of Kan. In order to maximise the chances of identifying the target protein 
5760 colony picks were performed for the whole transposon library six 96 well plates 





3.3.3.3.1 Dot Blots 
Colony picks were grown and 2 μL of each was transferred to nitrocellulose membrane 
via direct pipetting and air drying. A range of Moraxella catarrhalis strains were also 
grown and transferred using the same technique as controls. Once the dotted material 
had dried, 3% (w/v) bovine serum albumin (BSA; diluted in PBS-T) was used to block 
the non-specific binding sites for 1 hour at room temperature. After initial blocking the 
liquid was aspirated and 0.2 μg.mL-1 of CC1 in 1% (w/v) BSA-PBST, was applied to 
the membrane for 1 hour at room temperature. The membrane was then washed three 
times with PBS-T, the third wash was incubated for 5 min for before being decanted. 
Anti-human-Fc conjugated to alkaline phosphatase diluted to 1 μg.mL-1 in 1% (w/v) 
BSA in PBS-T with 0.05% (w/v) NaN3 was added to each strip and incubated for 1 
hour at room temperature. The blots were washed as before and developed for 15 
mins using developing buffer (6.6 μL∙mL-1 of NBT and 3.3 μL∙mL-1 of BCIP in AP 
buffer). 
Once the blots had developed any dots which showed weak/ zero binding to CC1 were 
then identify and those colonies selected for further study.  
A series of successive immunodot blots were carried out to whittle down the target list, 
each blot followed much the same process. In each successive screen a more 
concentrated solution of CC1-Fc was utilised. 0.4 μg.mL-1 of CC1-Fc in screen 2, 
0.6 μg.mL-1 of CC1-Fc in screen 3, 0.8 μg.mL-1 of CC1-Fc in screen 4, 1 μg.mL-1 of 
CC1-Fc in screen 5. 
Colonies were grown and freeze thaw lysis was performed, lysates were then 




membrane via direct pipetting and vacuum drying. Non-specific binding sites were 
blocked for 1hr at room temperature with 3% (w/v) bovine serum albumin (BSA; diluted 
in PBS-T). CC1-Fc diluted in 1% (w/v) BSA-PBST, was applied to the membrane for 
1 hour at room temperature. The membrane was then washed three times with PBS-
T, the third wash was incubated for 5 min. Anti-human-Fc conjugated to alkaline 
phosphatase diluted to 1 μg.mL-1 in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 
was added to each strip and incubated for 1 hour at room temperature. The blots were 
washed as before and developed for 15 mins using developing buffer (6.6 μL∙mL-1 of 
NBT and 3.3 μL∙mL-1 of BCIP in AP buffer). 
3.3.3.3.2 PCR 
Colonies that did not bind to CC1, were subject to PCR with the BOMP specific 
primers. 7μL nuclease free water (ddH2O), 0.5 μM of forward and reverse primers, as 
well as 1 ng.μL-1 genomic DNA were added to 10 μL CloneAmp™ high fidelity PCR 
premix in a 0.2 mL PCR tube to form the PCR mix. 
PCR was performed under the following conditions: initial denaturing 98 °C 5 min; 
followed by 30 cycles of: denaturing 98 °C 10 sec, annealing X °C 15 sec, extension 
72 °C 5 sec∙kBase-1 DNA; finished by 72 °C 5 min for the final extension. The 
annealing temperature of the primers varied (table 1).  
Colonies in which PCR products which had increased by 1221 bp due to the insertion 





4 RESULTS – STABLE CC1 SECRETING CELL LINE 
 
 Creating a stable CC1-Fc secreting cell line  
To examine the CC1 binding capabilities of Moraxella catarrhalis a large amount of 
CC1 was required on hand for multiple experiments. Prior to this project the laboratory 
had previously either bought CC1-Fc commercially or produced it transiently, both of 
these systems limited the amount of CC1 that could be accessed immediately. It was 
decided that in order to have as much CC1 as required, a stable CC1-Fc secreting cell 
line should be constructed. 
 
 Optimising the zeocin concentration required to select for successful 
transfection  
Prior to any transfections taking place it was necessary to optimize the concentration 
of zeocin which would be used as a selective pressure, ensuring only successfully 
transfected cells survived. The zeocin resistance of the transfected cells was conferred 
by the Sh ble gene encoded by the pINFUSE-hIgG2-Fc2 plasmid. In order to 
determine the optimal zeocin concentration a kill curve was undertaken. This kill curve 
exposed untransfected CHO cells to a range of zeocin concentrations for a period of 
10 days. Cells were checked daily under a microscope and a visual assessment of 
percentage survival was determined and antibiotic concentration was maintained. 
after a 10-day observation period the optimal zeocin concentration required for the 





 Amplifying the CC1-Fc gene from the full length CC1 gene  
In order to create a stable CC1 secreting cell line, it was necessary to first amplify and 
clone the CC1-Fc isoform encoding DNA. PCR was used to amplify the correct CC1 
isoform from genomic DNA obtained from CC1 expressing HeLa cells (figure 5). Prior 
experiments examining CC1 had used primers which were unsuitable for amplifying 
CC1-Fc. As evident by the four bands in lane 3 & 4, these primers appeared to be 
binding to multiple sites which in turn produced undesirable non-specific products. As 
such new forward and reverse primers were designed which enabled the amplification 
of the transmembrane domain lacking isoform of CC1 only. This resulted in the 1000 
kb band in lane 2 & 5 which, according to sequence data obtained from Uniprot, 
corresponded to the expected molecular weight of the target isoform. These primers 
were also designed to be used in ligation independent cloning and as such had 3’ 
regions which were homologous with pINFUSE that had been linearized using EcoRV 
and BglII restriction enzymes. As both enzymes were compatible with NEBuffer 3.1 a 
double digest reaction was undertaken at 37 °C for 15 minutes which resulted in the 





Figure 5 Amplification of human CC1-Fc from HeLa CC1 genomic DNA. 
 
PCR of CC1-Fc using genomic DNA from HeLa CC1 cells using either the CC1 forward and reverse 
primers or CC1-Fc forward and reverse primers (appendix 1). 
PCR product were separated using 0.8% agarose TBE gel electrophoresis. Lane 1 Generuler 1 kb Plus 
DNA ladder. Marker sizers are indicated in base pairs (bp).  
Although PCR performed utilising older CC1 primers produced a band at approximately 1000 bp 
corresponding to the expected size of CC1-Fc isoform (Lane 3 & 4), multiple other products were also 
observed at 1500 bp, 900 bp, and 500 bp. New CC1-Fc specific primers were designed and produced 
a single product of approximately 1000 bp in size which corresponds with the expected size of the CC1-















Figure 6 Linearization of pINFUSE-hIgG2-Fc2 
 
Comparing supercoiled pINFUSE-hIgG2-Fc2 with the same plasmid linearized using the restriction 
enzymes EcoRV and BglII. 
Plasmid DNA was separated using 0.8% agarose TBE gel electrophoresis. Lane 1 Generuler 1 kb Plus 
DNA ladder. Marker sizers are indicated in base pairs (bp).  
Uncut plasmid (lane 4 & 5) produced two distinct products at approximately 5000 bp and 1500 bp which 
corresponds to 2 possible plasmid conformations. The larger band representing a relaxed confirmation 
whilst the smaller band represented a lower energy supercoiled state. When pINFUSE was digested 
with both EcoRV and BglII a product of approximately 4500 bp was produced (Lane 2 & 3), this 








4.3.1 Cloning of CC1-Fc PCR product into XL10 Gold cells 
Prior to transfection it was necessary to increase the amount of pINFUSE-CC1-Fc 
available and as the gene was to be transfected into eukaryotic cells, XL10 gold cells 
were used. Xl10 gold ultracompetent cells underwent heat shock in the presence of 
the plasmid and were plated onto LB plates supplemented with zeocin for overnight 
growth. After a period of overnight growth over 100 distinct colonies were observed 
whilst the control plate using untransformed showed no growth, ten colonies were 
selected and expanded in zeocin supplemented LB broth. Two of the ten colonies did 
not grow when placed in the growth medium. The remaining eight colonies were 
subject to plasmid extraction via the QAIGEN MiniPrep kit; during this process four of 
the colonies were mishandled and thus excluded from the rest of the screening 
process. The four remaining colonies had the plasmid successfully extracted and were 
examined using PCR and gel electrophoresis (figure 7) which confirmed that 
transformation was successful in all four of the chosen colonies.  
After the successful transformation and extraction of pINFUSE-CC1-Fc from XL10-
Gold cells, the plasmid was relinearized (figure 8). The NotI restriction enzyme was 
used to create a linear pINFUSE plasmid containing CC1-Fc in order to increase the 
chances of integration with host cell genomes thus enabling continuous stable protein 
expression. The single 5398 bp band in lane 1 corresponded to the expected size of 








Figure 7 Amplification of CC1-Fc from transformed XL10 gold cells 
 
PCR of CC1-Fc using plasmid DNA extracted from XL10 gold cells transformed with pINFUSE-CC1-Fc 
using the CC1-Fc forward and reverse primers (appendix 1). PCR product were separated using 0.8% 
agarose TBE gel electrophoresis. Lane 1 Generuler 1 kb Plus DNA ladder. Marker sizers are indicated 
in base pairs (bp).  
Colony picks 1, 3, and 4 all produced a single product of approximately 1000 bp in size which 
corresponds with the expected size of the CC1-Fc isoform lacking any intracellular or transmembrane 
regions (Lanes 3, 5, 6). Colony pick 2 also produced a single product at approximately 1000 bp although 








Figure 8 Linearization of pINFUSE-CC1-Fc 
 
Linearisation of the pINFUSE-CC1-Fc plasmid with the NotI restriction enzyme in preparation for 
transfection.  
Plasmid DNA was separated using 0.8% agarose TBE gel electrophoresis. Lane 1 Generuler 1 kb Plus 
DNA ladder. Marker sizers are indicated in base pairs (bp).  
When pINFUSE-CC1-Fc was digested with NotI it produced a single linear product of approximately 
5500 bp (Lane 3), this corresponded with the expected combined size of the plasmid and the gene of 
interest.  
 
Data representative of products obtained on several occasions; repeats performed by undergraduate 












 Assessing for CC1 production in transfected cells. 
CHO cells were transfected with linear pINFUSE-CC1-Fc DNA using the lipid-based 
transfection reagent lipofectamine 3000. Prior to selection of a monoclonal population 
it was necessary to determine that the transfected cells were producing CC1, as such 
the supernatant from the transfected cells was collected.  
The supernatant from the transfected CHO cells was subject to serial dilutions (figure 
9), dots 1 through 3 demonstrated a binding for A0115 that was significantly higher 
than background. Whilst dot four displayed reduced binding equal to levels observed 
in the negative control dots. The last dot in the series displayed no binding for the anti-
CEACAM antibody at all, below the background level binding displayed in the negative 
control dots. Although it is not clear why the binding of dot 5 was below that of 
supernatant from untransfected cells, it was clear that the first three dots were binding 













Figure 9 Assessing the CC1-Fc secretion of transfected CHO cells. 
  
A dot blot was performed to determine if the transfected CHO cells were secreting CC1-Fc. Supernatant 
was collected from the CHO cells transfected with the pINFUSE-CC1-Fc DNA at days 3 and 7 post 
transfection. The collected supernatant was pooled, and a series of serial dilutions were carried out 
were each successive dot was half as dilute as the previous dot (dot 1-5). Supernatant obtained at the 
same intervals from untransfected CHO cells were used as negative controls (dots 6-7).  
Membrane A was overlaid with primary antibody 1 μg.mL-1 A0115, then secondary antibody 1 μg.mL-1 
Goat-anti-Rabbit-IgG(Fc)-AP.  
Transfected supernatant dilutions 1-3 produced dots which were significantly darker than the negative 
control dots indicating that CC1 was detected in the supernatant. Dilution 4 produced a dot which was 
comparable to the control dots, suggesting that at this level of dilution no CC1 could be detected. 
Dilution 5 produced a dot that was weaker than the negative control dots.  
Membrane B acted as a negative control with only a secondary antibody overlay. Data representative 











 Assessing the production of CC1-Fc by monoclonal populations of 
transfected CHO cells. 
After confirmation that the transfected CHO cells were producing CC1-Fc, some of the 
cells were reseeded into a 96 well plate in order to select for a monoclonal CC1 
secreting population, whilst the rest were reserved as a polyclonal population in a T75 
flask. After a period of selection 5 monoclonal populations were identified and their 
growth expanded in T25 flasks. During passaging the supernatant of all monoclonal 
populations was collected and examined via immune dot blot.  
50 μL of each monoclonal supernatant was vacuum dotted onto nitrocellulose 
membrane and overlaid with A0115 (figure 10) in order to assess the comparative 
amounts of CC1-Fc produced by each of the monoclonal populations. The supernatant 
from each of the monoclonal populations visually demonstrated a significantly higher 
binding to A0115 compared to the control blots containing the supernatant from 
untransfected cells. No single monoclonal population bound more strongly to A0115 
than the other which indicated that each population was producing a similar amount 











Figure 10 Assessing the CC1-Fc production of monoclonal CC1-Fc secreting CHO 
populations 
 
A dot blot was performed to determine if the monoclonal populations of transfected CHO cells were 
secreting CC1-Fc. Supernatant was collected from the selected monoclonal populations of CHO cells 
transfected with the pINFUSE-CC1-Fc DNA. The collected supernatants were blotted onto 
nitrocellulose membrane (dots 1-5) Supernatant obtained from untransfected CHO cells were used as 
negative controls (dots 6-7).  
Membrane A was overlaid with primary antibody 1 μg.mL-1 A0115, then secondary antibody 1 μg.mL-1 
Goat-anti-Rabbit-IgG(Fc)-AP. All transfected supernatants produced dots which were visually stronger 
than the background levels observed in the negative control dots indicating that CC1-Fc was secreted 
by all monoclonal populations.  
Membrane B acted as a negative control with only a secondary antibody overlay.  
Data representative of products obtained on several occasions; repeats performed by undergraduate 




















 Determining the concentration of CC1-Fc  
Before CC1-Fc could be of any real use in experiments it was necessary to determine 
the concentration of the purified protein. This was done via BCA assay. This assay 
was selected as it has a high sensitivity over a wide range of concentrations, enabling 
precise results as long as the protein concentration is between the ranges 20 μg∙mL-1 
or 2000 μg∙mL-1. The BCA assay determined the CC1-Fc concentration to be 227 













Figure 11 Determining the concentration of purified CC1-Fc 
 
A BCA assay was performed to assess the concentration of the CC1-Fc secreted by the transfected 
CHO cells. After purification via protein Sepharose A, the CC1-Fc was compared to a set of standards 
ranging from 20-2000 μg.ml-1. The concentration of the protein was proportional to the amount of 
reduced Cu2+, which corresponds to the intensity of the resulting purple coloured complex. A reading 
was taken at 562 nm (the wavelength most strongly absorbed by the 2BCA-Cu+ complex) and a graph 






















 Comparing the rD-7 binding of CC1-Fc and oCC1-Fc. 
To examine the fidelity of the newly produced CC1-Fc another immune dot bot was 
undertaken which compared its binding capabilities to a verified CC1-Fc sample. An 
OpaLess strain of Neisseria and rD-7, a recombinant peptide spanning the CEACAM 
binding region of UspA1 were vacuum blotted onto nitrocellulose membrane in 
triplicate. The non-specific binding sites were blocked before being overlaid with either 
CC1-Fc produced in the laboratory or the oCC1-Fc (figure 12). The strong binding to 
rD-7 appeared to be identical for both CC1-Fc and oCC1-Fc. Whilst no binding 

















Figure 12 Comparing the binding of CC1-Fc and oCC1-Fc 
  
A dot blot was performed to determine if the secreted CC1-Fc produced by the transfected CHO cells 
performed the same as oCC1-Fc when used experimentally. Purified rD-7 (dots 1-3) and OpaLess (dots 
4-6) were blotted onto nitrocellulose membranes.  
Membrane A was overlaid with CC1-Fc 0.2 μg.mL-1, then secondary antibody 1 μg.mL-1 Rabbit-anti-
Human-IgG(Fc)-AP.  
Membrane B was overlaid with oCC1-Fc 0.2 μg.mL-1 then secondary antibody 1 μg.mL-1 Rabbit-anti-
Human-IgG(Fc)-AP.  
Both membrane A and B developed identically, as expected dots 1-3 displayed strong binding to both 
CC1-Fc and oCC1-Fc, whilst dots 4-6 did not bind to either CC1-Fc or oCC1-Fc.  
 












 SDS-Page gel and western blot to determine the purity of CC1-Fc. 
Whilst immune dot blots showed that the CC1-Fc bound to rD-7 and OpaLess 
identically to oCC1-Fc it was necessary to verify that the proteins also behaved the 
same under different conditions. An SDS-Page gel was performed to compare the 
purity and the molecular weights of both CC1-Fc and oCC1-Fc as well as older stock 
sample of CC1 (figure 13). Although CC1-FC is a is predicted to be a 57.7 kDa protein 
it is highly glycosylated and often dimerises therefore appearing much larger on SDS-
Page gels than in actuality. Both CC1-Fc (lane 1) and oCC1-Fc (lane 2 & 3) show faint 
bands at approximately 57 kDa as well as stronger bands at 250 kDa. The older CC1 
sample in lane 5 shows a strong band at 50 kDa, which could be an antibody fragment, 
another band may also have been seen at approximately 25 kDa but it was run off the 
gel. The sample in lane 5 also demonstrated extensive laddering, this is indicative of 
a contaminated or degraded sample, possibly due to fragmentation or overuse of the 
sample. 
A western blot was performed to compare the functions of CC1-Fc to oCC1-Fc under 
denaturing conditions. The proteins were run on an SDS-PAGE gel before being 
transferred to nitrocellulose and overlaid with the CEACAM specific antibody A0115 
(figure 14), which binds to the N terminus of the protein. Both CC1-Fc (lane 2) and 
oCC1-Fc (lane 3 & 4) show strong diffuse bands at 250 kDa, although the band in lane 






Figure 13 SDS-Page gel comparing CC1-Fc to oCC1-Fc 
 
An SDS-Page gel was run and developed via Coomassie stain, to visually compare the molecular 
weights of CC1-Fc to two fractions of oCC1-Fc, as well as an older stock that was suspected to be CC1.  
Protein samples were separated by running a 7.5% resolving gel and 4% stacking gel at 200 V for 1 
hour 30 minutes. Lane 1 Precision Plus Protein Dual Colour Standards. Marker sizers are indicated in 
kilo-Daltons (kDa).  
Strong bands at approximately 250 kDa were evident in all four samples of protein, this is significantly 
larger than the expected weight of CC1-Fc as indicated by its protein sequence but does correspond to 
the expected size of the protein when the extensive glycosylation of CC1 is considered. Faint bands at 
approximately 50 kDa were also present in lanes 2-4 (CC1-Fc, oCC1-Fc1, and oCC1-Fc2), these bands 
could be antibody fragments. This 50 kDa band was also present in lane 5 (suspected CC1 stock) 
although it was significantly stronger than the bands from the other samples. In contrast to lanes 2-4, 
the suspected CC1 stock (lane 5) also displayed multiple other bands between 250 kDa and 37 kDa in 








Figure 14 Western blot comparing rCC1 to vCC1. 
 
A western blot was performed, to visually compare the fidelity of CC1-Fc to two fractions of oCC1-Fc. 
Proteins were separated by SDS-Page gel and the gel transferred to nitrocellulose membrane at 350 
mA for 60 min. Once transferred the membrane was overlaid with primary antibody A0115 and 
secondary antibody Goat-anti-Rabbit-IgG(Fc)-AP both at a concentration of 1 μg.ml-1. Lane 1 Precision 
Plus Protein Dual Colour Standards. Marker sizers are indicated in kilo-Daltons (kDa).  
Strong diffuse bands were present at approximately 250 kDa were evident in lanes 2-4 (CC1-Fc, oCC1-
Fc1and oCC1-Fc2), which corresponds to the expected size of CC1-Fc as determined in figure 13. The 
band in lane 3 was stronger than the band produced by CC1-Fc (lane 2) this may be due to disparities 
in concentration of the tested proteins.  
 
Data representative of products obtained on several occasions; repeats performed by undergraduate 









 Conclusions  
Overall the results of the experiments suggest that CC1-Fc gene was successfully 
transfected into the CHO cell genome, resulting in a stable CC1-Fc secreting cell line. 
The purified protein responds functionally identically to stock CC1 in interactions with 
both A0115 and rD-7. The total concentration of CC1-Fc purified from 1.5 L of 
supernatant was 226.8 μg∙mL-1, the supernatant in this case was obtained from both 
poly and monoclonal populations of transfected cells. In the future purifying CC1-Fc 
from the supernatant of monoclonal clonal populations may produce a higher 

























5 RESULTS – ASSESSING THE CC1 BINDING PROPERTIES OF 
MX13L  
 CC1 adhesive properties of Moraxella catarrhalis strains  
Unpublished observations within the Hill group identify two variants of ATCC25240 
with different CC1 binding properties, termed MX13L and MX13D. Although 
ATCC25240 expressed a truncated UspA1 protein lacking the rD-7 region, the MX13L 
variant was shown to bind to CC1, despite lacking the functional region required to do 
so. A number of experiments where undertaken to confirm that MX13L did in fact lack 
an rD-7 region and still bind to CC1. 
 
5.1.1 Assessing the binding of MX13L to CC1 
Moraxella catarrhalis strains MX13L, MX13D, ATCC25240, MX13ΔUspA1, MX2 and 
ATCC25239 were selected to compare their binding to CC1-Fc. Purified rD-7 acted as 
a positive control, whilst the OpaLess strain of Neisseria acted as a negative control. 
The selected strains were grown overnight and standardised to A280 OD 0.5. The non-
specific binding sites were blocked before being overlaid with either CC1-Fc or oCC1-
Fc (figure 15). As expected, MX2 and rD-7 showed strong binding to CC1 this was 
due to the high specificity of the rD-7region for CC1. MX13L and MX13ΔUspA showed 
reduced receptor binding compared to rD-7. Whilst at a lower level than that observed 
for MX2 or pure rD-7, the CC1-Fc binding of both MX13L and MX13ΔUspA was greater 
than MX13D or the parent strain ATCC25240. Additional controls included an overlay 
with anti-Human only, as expected this negative control showed no binding by any of 



























Figure 15 Dot blot assessing the CC1 binding of MX13L 
 
A dot blot was performed assess the CC1 binding capabilities of various Moraxella catarrhalis strains. 
All lysates and proteins were standardised to OD600 0.5. The lysates of selected Moraxella catarrhalis 
strains; MX13L, MX13D, ATCC25240, MX13ΔUspA1, MX2, and ATCC25239 were blotted onto 
nitrocellulose membrane (dots 1-6). OpaLess (dot 7) and rD-7 (dot 8) acted as negative and positive 
controls respectively.  
Membrane A was overlaid with primary antibody 1 μg.mL-1 CC1-Fc. Membrane B was overlaid with 
1 μg.mL-1 oCC1-Fc. Both membranes A & B were overlaid with secondary antibody 1 μg.mL-1 Rabbit-
anti-Human-IgG(Fc)-AP.  
Membrane C acted as a negative control and was only overlaid with secondary antibody.  
As expected, dots 5 & 8 showed very strong binding. Dots 1 & 4 also displayed strong binding to CC1, 
despite both lacking the UspA1 protein. Dots 2, 3 & 6 all displayed reduced binding to CC1. All of the 
Moraxella catarrhalis strains displayed a binding for CC1 greater than OpaLess.  
 








5.1.2 Comparing the UspA1 sequences of the MX13L parent strain ATCC25240 
to a functional UspA1 protein 
Pairwise alignment between a functional UspA1 sequence and the ATCC25240 
sequence highlights the incomplete nature of the UspA1 protein produced by 
ATCC25240 (figure 16). There are extensive regions of the BBH18 UspA1 sequence 
that are not present in the ATCC25240 sequence as well as amino acid substitutions 
in the regions that do overlap. The analysis of both sequences also demonstrates that 
whilst the minimal cc1 binding region of rD-7 is clearly present in the BBH18 UspA1 
















Figure 16 Amino acid sequence comparison of functional a UspA1 protein and the UspA1 protein of ATCC25240 
 
Pairwise alignment of the UspA1 protein sequences of the Moraxella catarrhalis strains BBH18 and ATCC25240 was performed using the ‘Multiple sequence 
alignment with hierarchical clustering’ tool. Identical amino acids between each of the proteins are highlighted in blue whilst the predicted minimal CC1 binding 




5.1.3 Determining the presence of the UspA proteins  
Pairwise alignment data was corroborated by the use of UspA1 and UspA2V specific 
primers, neither of which produced a band with ATCC25240 (figure 17). In the case of 
UspA2V this was because ATCC25240 does not encode a copy of this gene in its 
genome. Although ATCC25240 does encode a UspA1 gene it is heavily truncated and 
missing the part of the sequence required for successful amplification with the UspA1 


















Figure 17 Amplification of UspA1 and UspA2 from MX13L  
 
PCR of UspA1 and UspA2 from either MX13L, MX2 or MX1 DNA using either the UspA1 or UspA2 
primers (appendix 1). PCR product were separated using 0.8% agarose TBE gel electrophoresis. Lane 
1 & 4 Generuler 1 kb Plus DNA ladder. Marker sizers are indicated in base pairs (bp).  
PCR performed utilising UspA1 primers in conjunction with MX13L DNA (lane 2) produced no band, in 
contrast PCR with the same primers against MX2 DNA (lane 3) produced a single band at approximately 
2500 bp. Using the UspA2 primers to amplify MX13L DNA (lane 5) also produced no product, whilst 
amplification of MX1 DNA (lane 6) produced a single 2000 bp band. This indicated that MX13L did not 
encode for either UspA1 or UspA2. Due to sequence similarities between UspA2 and UspA2V & H, 
primers for UspA2 would also have amplified either of the variant genes as well (as in the case of MX1 










5.1.4 Determining the presence of the CC1 binding region rD-7 
Selected Moraxella catarrhalis lysates were dotted onto a nitrocellulose membrane 
and overlaid with an anti-rD-7 antibody, R38 (figure 18). Purified rD-7 acted as a 
positive control, whilst a duplicate membrane overlaid with secondary antibody only 
acted as a negative control. As expected MX2 and rD-7 were bound by anti-rD-7. 
Moraxella catarrhalis strains, MX13L to MX13D and MX13ΔUspA2 displayed 
comparable binding to the negative control strip. All lysates produced a negative result 
when blocked with anti-Rabbit only (data not shown). This experiment in conjunction 
with previous observations, including a proteinase k digest, proved that MX13L was 
not expressing the traditional Moraxella catarrhalis CC1 binding protein and therefore 
















Figure 18 Dot blot to detect the rD-7 region. 
  
A dot blot was performed to detect the presence of the rD-7 region in various Moraxella catarrhalis 
strains. All lysates and proteins were standardised to OD600 0.5. The lysates of selected Moraxella 
catarrhalis strains; MX13L, MX13D and MX2 were blotted onto nitrocellulose membrane (dots 1-3). rD-
7 (dot 4) and MX13ΔUsp (dot 5) acted as negative and positive controls, respectively.  
Membrane A was overlaid with primary antibody 1 μg.mL-1 anti-rD-7, then secondary antibody 1 μg.mL-1 
Goat-anti-Rabbit-IgG(Fc)-AP.  
Membrane B acted as a negative control with only a secondary antibody overlay. 
Dots 1, 2 and 5 did not produce a dot and therefore did not bind to the anti-rD-7 antibody. Whilst as 
expected dots 3 and 4 both produced a strong reaction to the primary antibody. These results indicate 
that neither MX13L nor MX13D were producing a rD-7 region.  
 










5.1.5 Looking for the CC1 binding ligand 
Following the determination that the rD-7 region of UspA was not responsible for the 
CC1 binding properties of MX13L, a western blot was run to determine the molecular 
weight of the novel protein (figure 19). The samples were boiled for 5 mins to denature 
the proteins in the lysate. The SDS-Page gel was run at 200 V for 1.5 hrs and the 
proteins were then transferred to a nitrocellulose membrane. The membrane was then 
overlaid with 0.2 μg∙mL-1 CC1-Fc. MX2 produced a band at 100 kDa which 
corresponds with UspA1. MX13L, MX13D and ATCC25240 as well as OpaLess all 
produced no bands. Although OpaLess was expected to produce no bands as it lacked 
the required adhesin, the other Mx isolates were expected to produce bands as they 
do bind CC1. The total lack of bands means that the novel CC1 adhesin is heat or 
detergent modifiable, which could be indicative of it being a more labile protein than 
UspA1 e.g. a beta barrel protein. Additional attempts to elucidate the molecular weight 
of the protein were unsuccessful, as native western blots produced a similar result as 
above. Unlike the CC1 specific binding sequence of UspA1, the highly labile nature of 







Figure 19 Western blot to compare the CC1 binding of various Moraxella catarrhalis 
strains 
 
A western blot was performed to identify the molecular weight of the novel CC1 binding protein. Proteins 
were separated by SDS-Page gel and the gel transferred to nitrocellulose membrane at 350 mA for 60 
min. Once transferred the membrane was overlaid with primary antibody CC1 and secondary antibody 
Rabbit-anti-Human-IgG(Fc)-AP both at a concentration of 1 μg.mL-1. Lane 1 Precision Plus Protein Dual 
Colour Standards. Marker sizers are indicated in kilo-Daltons (kDa).  
No bands were evident in lanes 2-4 (MX13L, MX13D, ATCC25240), which indicates that the novel 
adhesin is heat modifiable. Lanes 5 and 6 (OpaLess and MX2) acted as negative and positive controls 
respectively, with MX2 (lane 6) producing a single band at approximately 100 kDa.  
 









 Identifying a Novel CC1 binding protein  
Experiments analysing the CC1 binding capabilities of Moraxella catarrhalis species 
MX13L identified a novel CC1 binding protein, separate from the traditional adhesin 
UspA1, which is highly labile. The heat sensitive nature of this protein indicates that it 
is potentially a beta barrel, as other labile adhesins such as the OPA proteins of 
Neisseria are also beta barrel structures. In order to create a potential target list of 
proteins a bioinformatic analysis of the proteins in ATCC25240 was required.  
 
5.2.1 Narrowing down the list of target proteins 
In order to narrow down the potential list of target proteins the PSORTdb was used to 
determine the subcellular localisation of all proteins found in the parent strain 
ATCC25240. PSORTdb is a database collating the subcellular localisation of proteins 
for bacteria and archaea. The information contained in the database is derived from 
laboratory verified experiments as well as computational predictions. PSORTdb 
generated a breakdown of the proteins present at each subcellular localisation. Of the 
1687 proteins identified in ATCC25240 only 2% where predicted to be outer 
membrane proteins (figure 20). Unfortunately, PSORT cannot predict the structure of 
a protein. In order to identify which of the outer membrane proteins were beta barrel 
structures another program was used.  
In order to further narrow down the list it was necessary to identify which of the outer 
membrane proteins were beta barrel structures, as such a program called BOMP was 
utilised. BOMP is a program which can predict if a protein is a beta barrel outer 




Membrane protein Predictor (BOMP) program identifies BOMPs through a two-part 
system. First it analyses the given sequence for the specific C-terminal pattern typical 
of many integral β-barrel proteins. The second step the program undertakes is 
searching the sequence for stretches of amino acids typical of transmembrane β-
strands. Using BOMP reduced the number of potential targets from 35 to 19.  
After analysing the genome of ATCC25240 with PSORT and BOMP, a list of 19 
potential targets was generated. Using the NCIB accession sequence assigned to 
each of the proteins, the nucleotide sequence of each protein was obtained. Accessing 
the accession sequence of each protein identified 2 proteins which were duplicates, 














Figure 20 PSORT analysis of ATCC25240 proteins localised in the outer membrane 
 
Analysis of the ATCC25240 genome by PSORTdb: A Database of Subcellular Localizations for Bacteria. Using a combination of 





Table 2 List of target proteins 
Combining the results of both PSORT and BOMP, and removing any duplicate 
proteins generated a list of 17 target proteins. Each protein was assigned an 























WP_003666550 BOMP 1 Hypothetical protein 
 
WP_038519905 BOMP 2 TonB-dependent receptor 
 
WP_003673045 BOMP 3 TonB-dependent receptor 
 
WP_038520226 BOMP 4 TonB-dependent receptor 
 
WP_003659887 BOMP 5 MipA/OmpV family protein 
 
WP_038519791 BOMP 6 Lactoferrin/transferrin family TonB-
dependent receptor 
 
WP_038520099 BOMP 7 Lactoferrin/transferrin family TonB-
dependent receptor 
 
WP_003661028 BOMP 8 Hypothetical protein 
 
WP_003659692 BOMP 9 Membrane protein 
 
WP_003660701 BOMP 10 Outer membrane protein assembly factor 
BamA 
 
WP_038520205 BOMP 11 Porin family protein 
 
WP_038518786 BOMP 12 TonB-dependent receptor 
 
WP_003667703 BOMP 13 TonB-dependent receptor 
 
WP_038519721 BOMP 14 ShlB/FhaC/HecB family hemolysin 
secretion/activation protein 
 
WP_003669513 BOMP 15 LPS-assembly protein LptD 
 
WP_038519603 BOMP 16 Hypothetical protein 
 






 Analysing the target proteins experimentally  
Bioinformatic analysis of the ATCC25240 genome detected 35 outer membrane 
proteins; of those only 17 met the experimentally indicated criteria (beta barrel 
structure). In order to assess the CC1 binding capabilities of the target proteins, each 
of the proteins were to be individually cloned into and expressed by E. coli. Adhesion 
assays utilising the transformed E. coli were undertaken to quantify the binding abilities 
of each target protein.  
 
5.3.1 Selecting a plasmid 
To facilitate the exploration of the target proteins CC1 binding abilities, the plasmid 
pOAF was utilised as a vector for E. coli transformations. This vector encodes the E. 
coli N-terminal signal peptide OmpA ahead of the gene of interest, which should 
facilitate the recombinant proteins to be expressed on the surface of E. coli , this allows 
for the CC1 binding properties of each protein to be evaluated. The presence of the 
lac operator with the plasmid sequence also permits for blue white screening, this 
process allowed for successfully transformed bacteria to be easily selected for further 
culture and confirmatory PCR.  
 
5.3.2 Primer design  
Primers which enabled ligation independent cloning for each of the target proteins 
were designed (table 1). In order to facilitate ligation independent cloning, each primer 




not interfere with the initial amplification of the target sequences from the ATCC25250 
genomic extract.  
 
 Cell adhesion assays 
To examine the CC1 binding capabilities of the target proteins more closely, whole-
cell binding assays were performed where the target proteins were expressed 
individually in their native form on the surface of bacteria. In order to do this target 
genes were amplified from MX13L genome using the specifically designed primers. 
The new recombinant bacteria were used then used to conduct adhesion assays in 
order to determine the adherence of the bacteria to HeLa cells modified to express 
CC1 on their surface 
 
5.4.1 Transformation of E. coli with target BOMPs  
Using the previously designed primers a series of PCRs were performed to amplify 
the DNA of each of the target BOMP. As each of the primers had different melting 
temperatures (appendix 1) these were performed individually or in small batches using 
CloneAmp HiFi PCR premix. The PCR premix was specifically designed to be used in 
conjunction with infusion cloning due to the hi fidelity polymerase. After successful 
amplification the PCR products were cleaned up via the PCR clean up kit. Using the 
infusion cloning enzyme in conjunction with the heat shock technique the BOMPs were 
cloned into stellar E. coli. After a period of overnight growth on LB plates supplemented 




were collected, and PCR/ gel electrophoresis performed to determine which of the 
colony’s had been successfully transformed (figure 21). Most of the target BOMPs only 
produced bands of the expected size although additional faint bands could be seen in 
several lanes; notably BOMPs 1 and 9. An additional band could also be found in 
BOMP 13, this additional band was comparable in strength to the correctly amplified 
band. This secondary band was also present in prior amplifications of BOMP 13 and 



















Figure 21 amplification of target BOMPs from MX13L genomic DNA.  
PCR of target genes using genomic DNA from MX13L using the specific target primers (table 1). PCR product were separated using 0.8% agarose TBE gel electrophoresis. 
Lane 1 of each gel contained Generuler 1 kb Plus DNA ladder. Marker sizers are indicated in base pairs (bp).  
Gel A: Lanes 2-5 (BOMP 1, 4, 7, & 11), produced bands at approximately 1200, 1100, 3000, and 700 bp respectively.  
Gel B: Lane 2 and 4 (BOMP 2 & 12), produced bands at approximately 2300, and 2800 bp respectively. 
Gel C: Lane 2-5 (BOMP 3, 5, 6, & 16), produced bands at approximately 2900, 800, 3300, and 2500 bp respectively. 
Gel D: Lane 2-6 (BOMP 8, 9, 14, 10, & 13), produced bands at approximately 1300, 1400, 2000, 2500, and 2500 bp respectively. Lane 6 (BOMP 13) produced two separate 
products of similar intensity, the larger band at approximately 2500 bp corresponds with the expected product size. A smaller band at approximately 300 bp was also evident 
(this band was present in PCR obtained from MX13L genomic DNA as well as from E. coli transformed with this gene). This smaller band may be a result of mispriming with 
a similar sequence. 
Gel E: Lane 2 and 3 (BOMP 15 & 17), both produced bands at approximately 2800 bp.           






5.4.2 Adhesion assays 
In order to visually compare the binding of E.coli cells transformed to express the target 
proteins, adhesion assays were undertaken whereby the transformed bacteria were 
used to infect either HeLa CC1 expressing cells or HeLa Neo cells which did not 
express CC1 on their surface. There were 2 distinct sets of adhesion assays carried 
out, 1 set utilised RPMI media without FBS whilst the other used FBS supplemented 
RPMI. This was done to ensure that tertiary binding reactions which require an 
intermediary protein present in blood serum to interact with CC1 were also observed. 
Untransformed E. coli cells did not appear to show any particular binding for HeLa 
CC1 cells compared to HeLa Neo cells, the addition of FBS to the media did not affect 
the background levels of adherence in any significant way either.  
E. coli cells transformed with BOMPs 8, 14, 6 and 17 all displayed an increase in 
adherence to HeLa CC1 cells in both the FBS supplemented and deficient adhesion 
assays, compared to the background levels observed in the untransformed E. coli 
(Figure 22). BOMPs 8 and 17 also had comparatively higher levels of infection than 
the other two target proteins. The levels of adherence in all the aforementioned target 
BOMPs was also elevated when compared to that observed in the same BOMPs 
interactions with HeLa Neos.  
Although an increase in adherence to CC1 expressing cells was evident in the 
adhesion assay follow up dot blots with lysates of the transformed bacteria did not 
show any elevated binding of CC1. The levels of adherence remained consistent with 






Figure 22 Adhesion assays examining the CC1 binding of E.coli transformed with 
MX13L BOMPs 
 
An adhesion assay was performed to assess the CC1 binding capabilities of each BOMP individually 
under conditions which mimic a Moraxella catarrhalis infection (both with and without the addition of 
FBS). HeLa CC1 cells were infected with E. coli BOMP cells (MOI 100) for a period of 3 hours, before 
being fixed with PFA. After fixation the cells were overlaid with primary antibody Rabbit-anti-E.coli and 
secondary fluorescent antibody AlexaFluor® 488 Goat-anti-Rabbit-IgG both antibodies at a 
concentration of 1 μg.mL-1, in order to visualise the bacterial cells. The cells were also exposed to DAPI 
in order to visualise the nucleus of the HeLa cells. Of the 17 BOMPs examined only four of the BOMPs 










Figure 23 Adhesion assays examining the CC1 binding of BOMP expressing E. coli  
 
A dot blot was performed in order to determine if the increase in binding to CC1 with the BOMPs 6,8, 
14, and 17 observed during adhesion assays with HeLa CC1 cells, was also evident other conditions. 
All lysates and proteins were standardised to OD600 0.5. The lysates of selected Moraxella catarrhalis 
strains; MX13L, MX13D and ATCC25240, (dots 1-3) and E. coli expressing BOMPs 6, 8, 14, and 17 
(dots 4-7) were blotted onto nitrocellulose membrane. rD-7 and OpaLess acted as positive and negative 
controls respectively (dots 8-9).  
Membrane A was overlaid with primary antibody 1 μg.mL-1 CC1, then secondary antibody 1 μg.mL-1 
Rabbit-anti-Human-IgG(Fc)-AP. Dots 4-7 did not appear to demonstrate any increase in binding to CC1, 
compared to the negative controls.  
Membrane B acted as a negative control with only a secondary antibody overlay.  
 












 Conclusions  
A daughter strain of ATCC25240, MX13L, is producing a novel CC1 binding protein 
which experiments indicate is beta barrel in nature. Bioinformatic analysis of the parent 
strain shortlisted 17 outer membrane proteins which were likely to be beta barrels, 
these proteins were subsequently expressed in E. coli and analysed for CC1 adhesion. 
Although four of the 17 shortlisted proteins demonstrated increased CC1 binding 
during adhesion assay experiments with CC1 expressing HeLa cells none of these 
proteins demonstrated the same increased affinity during dot blots. It was decided that 
it was necessary to pursue another avenue of research and a transposon library was 














6 RESULTS – TRANSPOSON LIBRARY OF MORAXELLA 
CATARRHALIS STRAIN MX13L 
 
Due to adhesion assay experiments producing no definitive results in regard to 
identifying the novel CC1 binding BOMP, a transposon library was undertaken. The 
EZ-Tn5™ <KAN-2>Tnp Transposome™ ability to randomly ‘jump’ into the bacterial 
genome was used to create random kanamycin resistant genetic knockouts. 
Immunoassays were then undertaken to determine which if any of the knockouts 
created were in the target protein.  
 
6.1.1 Colony picks  
When performing a transposon library, it is important to ensure that the colonies are 
not too densely packed as single colony is needed per colony pick to ensure that each 
colony represents a single knockout gene. In order to ensure that the colonies were 
not too closely packed onto the surface of each plate, the 23 μL volume of transformed 
cells were recovered in 977 μL of SOC media, bringing the total volume up to 1000 μL. 
The cell media was then spread over 10 HBHI plates supplemented with 20 μg.mL-1 of 
kanamycin.  
To maximize the likelihood of identifying the knockout protein required in a transposon 
library, it is necessary to perform at least twice as many colony picks as there are 
genes in the genome of the organism being studied. As there are 1799 genes in the 
ATCC ATCC25240 genome (the parent strain off MX13L) and more colony picks 




that 3 times as many colony picks as there are genes in the genome would be 
performed. Since 10 HBHI plates were utilized for colony growth and to ensure an 
even spread of colony picks it was determined that the same number of colonies 
should be chosen from each plate. In accordance with the decision to perform three 
times as many colony picks as genes in the ATCC25240 genome this would have 
required 5.7 96-well plates per HBHI plate. To maximise the use of resources as well 
as make the most of the transposon library it was decided that all available wells in 
each 96-well plate should be filled; thus six 96-well plates were used per HBHI plate 
resulting in 5760 total colony picks being performed. This is greater than 3.2 times as 
many genes in ATCC25240. 
 
6.1.2 Screening for colonies that did not bind CC1  
In order to identify the target protein a series of immuno-dot blot screens were 
performed to determine which of the colony picks had had the target gene knocked 
out by the transposon. The screening process was made more complicated by the fact 
that a positive result for the experiment was actually the absence of binding rather 
than a strong binding reaction as in most experiments.  
Each subsequent stage of the transposon library screening process utilised a slightly 
increased concentration of CC1-Fc. Screen 1 utilised a concentration of 0.2 μg.mL-1 of 
CC1-Fc, this was in accordance with the minimum levels of CC1-Fc that the target 
protein can reliably bind to. This information was obtained during previous experiments 
assessing the binding capabilities off MX13L to CC1. Initial screens used low 




that any isolates within this initial screen that did bind to CC1 were not eliminated due 
to false negatives which are more likely to occur at higher CC1 concentration. At the 
other end of the screening process, screen 5 utilised a much higher concentration of 
CC1-Fc at 1 μg.mL-1, this was to eliminate false positives that had passed through 
previous screens. Any isolates which produced a positive result at both high and low 
concentrations indicated that they were true positives completely lacking any CC1-Fc 
binding capabilities. This variation in CC1-Fc concentrations increased the reliability 
of the experiment by eliminating both false negatives and false positives at either end 
of the screening process. 
 
6.1.2.1 Screen 1  
The initial screening of the colony picks was done via hand dotting due to the number 
of colonies to be examined, as this process enabled more dots to fit onto a strip of 
nitrocellulose. In addition to the colony picks which were grown in 300 µL of HBHI 
broth supplemented with kanamycin series of standards were also prepared in the 
same manner excluding the presence of kanamycin. The standards MX13L, MX13D, 
rD-7 and OpaLess were used as a comparison, with rD-7 and OpaLess acting as 
examples of extremely strong binding and the absence of binding respectively. 2 μL 
of each isolate were hand dotted onto nitrocellulose paper and allowed to air dry. After 
blocking the non-specific binding sites with a 3% BSA solution the membranes were 
overlaid with 0.2 μg.mL-1 of CC1-Fc. This initial screening process tested the CC1-Fc 
binding capabilities of all 5760 colony picks (figure 24) [appendix 2]. The majority of 
colony picks showed binding which was compatible either MX13L or MX13D; 59% and 




increase in binding compared to their parent strain comparable to that of a functional 
rD-7 region. Only 489 (8%) of the isolates exhibited a lack of binding activity equivalent 
to that of OpaLess, which in the context of this experiment constituted a positive result. 
In addition to the colonies which had results comparable to that of the standards, 30 
dots were also deemed unreliable. These unreliable results were identified via 
ponceau staining prior to the initial 3% BSA block, which showed that little or no protein 
was present on the membrane. Colonies which produced dots with binding 
comparable to OpaLess as well as unreliable dots were carried forwards into the next 
















Figure 24 Graphical summary of dot blots assessing the CC1 affinity of randomly 
generated MX13L genetic knockouts.   
 
A dot blot was performed to assess the CC1 binding capabilities of the MX13L knockouts created by 
the ez tn5 transposon. 5760 colony picks were performed, and hand dotted onto nitrocellulose 
membrane. The lysates of selected Moraxella catarrhalis strains; MX13L, MX13D, ATCC25240, MX2, 
as wells as rD-7 & OpaLess acted as a series of standards to compare the binding of the colony picks. 
The membranes were primarily overlaid with 0.2 μg.mL-1 of CC1, before the secondary antibody 
1 μg.mL-1 Rabbit-anti-Human-IgG(Fc)-AP was applied.  



































Bar Chart displaying the relative CC1 binding affinity of 




6.1.2.2 Screen 2 
A total of 486 colonies from screen 1 were carried forwards into the second stage of 
the screening process these colonies were grown in 5ml of kanamycin supplemented 
HBHI broth and following freeze-thaw lysis were standardized to A280 OD 0.5. Using a 
vacuum manifold 50 microliters of each isolate were transferred to a nitrocellulose 
membrane and overlaid with 0.4 μg.mL-1 of CC1 (figure 25). This increase in CC1 
concentration indicated that 70.8% of the isolates carried forward bound to CC1. None 
of the isolates examined in screen 2 displayed increased binding to CC1. The isolates 
which did bind displayed an affinity comparable to either MX13L or MX13D. Unlike 
screen 1 the isolates in screen 2 were subject to freeze-thaw lysis prior to blotting, this 
process enabled all proteins to be released from inside the cell and maximised binding. 
This coupled with the increased CC1 concentration revealed that most of the isolates 
from screen 1 were false positives. Once again results comparable to the OpaLess 





































Figure 25 Screen 2 dots blots  
 
A dot blot was performed to assess the CC1 binding capabilities of the MX13L knockouts, which showed 
little binding to CC1 in the previous screen. All lysates and proteins were standardised to OD600 0.5. 
OpaLess and rD-7 (dots 493 & 494), as well as the lysates of selected ; MX2, MX13L, MX13D & 
ATCC25240 (dots 495-498) acted as a series of standards to compare the binding of the colony picks. 
The membranes were overlaid with primary antibody 0.4 μg.mL-1 of CC1, then secondary antibody 







6.1.2.3 Screen 3 
Screen 3 followed much the same procedure as screen 2; A280 OD 0.5 standardised 
lysates of isolates that demonstrated an affinity similar to OpaLess in the previous 
screen were vacuum dotted onto nitrocellulose membrane and overlaid with CC1. This 
screen used a concentration of 0.6 μg.mL-1 of CC1. 142 of the colonies from screen 2 
met the requirements for examination in screen 3 (figure 26). The increased CC1 
concentration revealed that of the examined isolates 82 merited further consideration 
whilst 9 isolates demonstrated higher levels of CC1 affinity comparable to rD-7. The 
















Figure 26 Screen 3 dot blot 
 
A dot blot was performed to assess the CC1 binding capabilities of the MX13L knockouts, which showed 
little binding to CC1 in the previous screen. All lysates and proteins were standardised to OD600 0.5. 
OpaLess and rD-7, as well as the lysates of selected Moraxella catarrhalis strains; MX13L, OpaLess, 
rD-7, MX13D, Mx2, ATCC25240 (dots 133-138) acted as a series of standards to compare the binding 
of the colony picks. The membranes were overlaid with primary antibody 0.6 μg.mL-1 of CC1, then 














6.1.2.4 Screen 4 
57.7% of the dots from the previous screen were carried forward into screen 4, as 
before the standardised lysates were overlaid with CC1 (figure 27). Once again, the 
concentration of CC1 was increased from 0.6 μg.mL-1 in the previous screen to 
0.8 μg.mL-1 in this screen to further narrow the result base down. Of the isolates 
examined only 11% produced results comparable to MX13L whilst 45% were similar 
to MX13D. the remaining 44% of dots appeared to display no particular affinity for CC1 
and thus were passed onto the next stage of the screening process. None of the dot 























Figure 27 Screen 4 dot blot 
 
A dot blot was performed to assess the CC1 binding capabilities of the MX13L knockouts, which showed 
little binding to CC1 in the previous screen. All lysates and proteins were standardised to OD600 0.5. 
OpaLess and rD-7, as well as the lysates of selected Moraxella catarrhalis strains; MX2, MX13D, 
ATCC25240, rD-7, Mx13L, OpaLess (dots 89-93) acted as a series of standards to compare the binding 
of the colony picks. The membranes were overlaid with primary antibody 0.8 μg.mL-1 of CC1, then 











6.1.2.5 Screen 5 
The 5th stage of the screening process was another immune dot blot using 1 μg.mL-1 
of CC1, this was the maximum amount of CC1 that the novel protein would bind to 
whilst still displaying an affinity that was weaker than rD-7. Only one of the examined 
isolates displayed a stronger than MX13L affinity for CEACAM. 64% of all the colonies 
examined in screen 5 demonstrated binding that was comparable to MX13D, the rest 



















Figure 28 Screen 5 dot blot 
 
A dot blot was performed to assess the CC1 binding capabilities of the MX13L knockouts, which showed 
little binding to CC1 in the previous screen. All lysates and proteins were standardised to OD600 0.5. 
OpaLess and rD-7, as well as the lysates of selected Moraxella catarrhalis strains; OpaLess, MX13D, 
ATCC25240, MX13L, Mx2, rD-7 (dots 37-42) acted as a series of standards to compare the binding of 
the colony picks. The membranes were overlaid with primary antibody 1 μg.mL-1 of CC1, then 





























6.1.3 Sequencing potential targets 
Of the total 5760 colonies examined only 0.2% isolates appeared to have a knockout 
mutation in the novel CC1 binding protein. the ideal next stage of the screening 
process would have involved sending all 12 isolates for whole genome screening but 
due to budget constraints that was not possible. The last step in the transposon library 
screening process utilised the primers previously designed for the adhesin assay 
experiments. As these primers had been specifically designed to bind to the beta 
barrel outer membrane proteins which had been identified as the best potential targets 
for the novel CC1 binding protein. DNA was extracted from each of the 12 isolates 
which displayed no CC1 binding affinity throughout the screening process. PCR using 
each primer was performed, if a knockout occurred in one of the target proteins an 
increase of 1221bp would be seen in the agarose gel which corresponded to the size 
of the transposon. If no band was evident, then the transposon had possibly inserted 
into a region of the genome which disrupted the primer sequence.  
Of the colonies examined 3.3C6, 3.3F2 and 9.6E7 (corresponding to original colony 
pick plate designation) displayed an increased band size in BOMP 8 from 1271 bp to 
2492 bp. A further 2 isolates displayed increased bands, 4.2H5 with BOMP 14 primers 
and 4.3B8 with 16. The rest of the isolates did not produce any visible increased band 
sizes. The PCR products of the 5 isolates which resulted in increased band sizes were 












Figure 29 Amplification of target BOMPs from transposon library colonies  
  
PCR of target genes using genomic DNA from MX13L knockout colonies, using the specific target 
primers (table 1). PCR product were separated using 0.8% agarose TBE gel electrophoresis. Lane 1 of 
each gel contained Generuler 1 kb Plus DNA ladder. Marker sizers are indicated in base pairs (bp). 
Lane 2, 3 & 6 (BOMP8 primers; colony 3.3C6, 3.3F2, & 9.6E7) produced bands at approximately 2500 
bp, an additional faint band at 1500 bp was also observed in lane 3. Lane 4 (BOMP14 primers; colony 
4.2H5) produced two bands at approximately 3000 bp and 1500 bp. Lane 5 (BOMP17 primers; colony 













Unfortunately, the sequencing returned results which were inconclusive, and the 
sequences appeared to be corrupted. All of the sequences from the PCR amplification 
were shorter than the bands viewed on the agarose gel, it is possible that the samples 
were contaminated or degraded during transit. Due to time constrains it was not 
possible to repeat the PCRs and resend products for sequencing. Three out of the five 
colonies which increased in size with the BOMP specific primers did so with the BOMP 
8 primers. This indicates that protein WP_003661028 which was designated BOMP 8 






















 Conclusions  
Moraxella catarrhalis was long considered a harmless coloniser of the respiratory tract 
but in the last few decades it has become an increasingly relevant clinical pathogen 
(Perez and Murphy, 2017). This bacterium is a major cause of otitis media infections, 
along with Streptococcus pneumoniae and H. influenzae. Unlike the conjugated 
duodecavalent pneumococcal vaccine (Plosker, 2013) programme for Streptococcus 
pneumoniae, Moraxella catarrhalis infections cannot currently be prevented with a 
vaccine. Recent studies examining the efficacy of the 13 valent pneumococcal vaccine 
have demonstrated that although the vaccine decreased the incidence of 
Streptococcus pneumoniae isolated from acute otitis media patients, the incidence of 
species which were not covered by the vaccine, especially Moraxella catarrhalis , 
increased (Kaur, Morris and Pichichero, 2017). Moraxella catarrhalis infections are on 
the rise with 10% of all COPD exacerbations per year implicating Moraxella catarrhalis 
species, thus increasing the bacteria’s impact not only on population morbidity but also 
its drain on health services.  
The need for more effective Moraxella catarrhalis treatments has never been more 
evident. The rapid spread of the BRO-1 and BRO-2 beta-lactam resistant phenotypes 
first observed in 1977 is a cause for concern. A recent study has shown that 100% of 
Moraxella catarrhalis isolates from middle ear fluid are beta-lactam resistant (Kaur, 
Morris and Pichichero, 2017). These beta lactamase enzymes are secreted in outer 




vicinity to survive, complicating the treatment of polymicrobial infections greatly 
(Schaar et al., 2011).  
In order to design a safe and effective vaccine against Moraxella catarrhalis more 
research into the bacterial mechanisms for infection must be undertaken, particularly 
in regard to adhesins. Moraxella catarrhalis main host ligand is CC1, the UspA1 and 
UspA2V proteins bind to CC1 using the sequence specific rD7 region. Designing a 
method to block CC1 Moraxella catarrhalis interactions would prevent Moraxella 
catarrhalis infection but in order for such treatment to be effective all CC1 interactions 
must be inhibited, the presence of an unknown CC1 adhesin protein would hinder the 
efficacy of treatments developed which only consider UspA proteins. If the novel 
adhesin proves to be conserved among strains as well as producing a protective 
antibody response it could be a potential candidate as a vaccine antigen target.  
This study examined the CC1 binding capabilities of a particular strain of Moraxella 
catarrhalis, MX13L, using a combination of immune overlay assays such as dot blots 
and western blots. Dot blot assays identified that MX13L a strain derived from the 
parent strain ATCC25240, which was confirmed to be lacking a functional rD-7 region, 
was interacting with CC1. Western blot analysis contradicted the dot blot finding, this 
indicated that the interaction between MX13L and CC1 was mediated by the structural 
confirmation of the novel adhesin much like the OPA proteins of Neisseria (Martin et 
al., 2016).  
 
In recent years a new field of study known as reverse vaccinology has developed, it 




candidates. Bioinformatic approaches have been met with success in aiding the 
identification of vaccine components (Sette and Rappuoli, 2010), this process allows 
for the mining of genomes to identify novel antigens which are less abundant or less 
immunogenic during infection that are likely to be missed. This project used 
computational analysis in conjunction with derived experimental data enabled a short 
list of likely target proteins to be identified. 
Using recombinant E. coli transformed to express outer membrane beta barrel proteins 
from Moraxella catarrhalis, adhesion assays were conducted against mammalian 
HeLa CC1 cells. Four proteins were identified as being probable targets: 
WP_038519791, WP_003661028, WP_038519721 and WP_038519295.  
WP_038519791 (BOMP 6) is a lactoferrin/transferrin family TonB-dependent receptor 
(TonB-tbp-lbp), this family of proteins primary import iron across the outer membrane 
during infection (Venture Institute, 2020). This family of receptors are unique to 
mammalian infecting bacteria. This protein appears to be highly conserved across the 
Moraxella catarrhalis species with over 90 strains displaying greater than 98% identity 
between the proteins.  
WP_003661028 (BOMP8) is a hypothetical protein, which although computationally 
predicted to exist has not yet been observed experimentally. It is a relatively small 
protein consisting of just 410 amino acid residues, the gene which encodes for this 
protein is localised within the OM channels region of the Moraxella catarrhalis genome. 
This protein is found across 60 different Moraxella catarrhalis strains and 
computational analysis marks it as part of the porin super family of proteins. Many 
species of bacteria use porins as adhesins, often this is a secondary function as in the 




catarrhalis the OMP CD porin is responsible for the adhesion to A549 human lung cells 
(Holm et al., 2004).  
WP_038519721 (BOMP14) is a ShlB/FhaC/HecB family haemolysin 
secretion/activation protein, it is involved in intracellular trafficking, secretion, and 
vesicular transport.  
WP_038519295 (BOMP17) is a BamA/TamA family outer membrane protein, it is a 
surface antigen protein related to OMP85 from N. meningitidis and N. gonorrhoeae, 
and the D15 antigen from H. influenzae, were it is highly conserved. The D15 protein 
produces a protective antibody response in many animal models and shows promise 
as a component for a universal H. influenzae vaccine (Loosmore et al., 1997). This 
protein is also conserved amongst Moraxella catarrhalis strains and regardless of its 
involvement in CC1 binding merits further study.  
Proteins of interest identified by adhesion assays were subject to further study, dot 
blots using the transformed E. coli did not confirm the adhesion assay findings. Due 
to the lack of definitive results with the adhesion assay experiments a transposon 
library was undertaken. Past studies have shown that this is an effective tool in 
identifying protein function. Transposon libraries have been used to identify the 
involvement of UspA2H in biofilm formation (Pearson and Hansen, 2007) as well as 
categorising the genes involved in the adherence of Moraxella catarrhalis to lung 
epithelial cells (de Vries et al., 2013). 
 
A transposon library of the MX13L strain was produced using the ez tn5 transposon. 




CC1. Using the primers which were previously designed for creating the recombinant 
E. coli, 5 colonies were identified as having mutations in proteins from the target list. 
Three of the colonies had mutations in the same protein, WP_003661028 (BOMP 8), 
which had also been indicated in adhesion assays as being a likely target. Another 
colony from the transposon library which did not bind CC1 had a mutation in 
WP_038519721 (BOMP 14), this protein was also implicated in adhesion assays as 
being a likely target.  
Sanger sequencing of the non CC1 binding transposon colonies which also displayed 
increased band size with the primers returned no definitive results. Due to time 
constraints it was not possible to send all 12 colonies from the transposon library that 
did not display a binding for CC1 for whole genome sequencing. In order to 
conclusively identify the novel CC1 adhesion all 12 of the transposon colonies which 
showed no binding for CC1 in screen 5 should have their genomes fully sequenced. 
Although unconfirmed by sequencing, WP_003661028 (BOMP 8) remains most likely 
protein to be the CC1 adhesin. Of the four BOMPs expressed by E. coli, that showed 
increased binding to HeLa CC1 cells, WP_003661028 (BOMP 8) demonstrated the 
most adherence compared to untransformed E. coli. This coupled with the fact that 3 
out of the 5 colonies that had an increased band size with the BOMP specific primers 
did so with the primers for WP_003661028 (BOMP 8), making WP_003661028 the 







There are some limitations to this study; experimental evidence such as the labile 
nature of the protein indicated that the target may be a beta barrel outer membrane 
protein. All further undertakings work off of the premise that this was the case as only 
BOMP specific primers were designed and used.  
In the case of the transposon library time constraints limited the number of colonies 
which could be sequenced. As such using PCR with BOMP specific primers 
determined that 5 out of the 12 colonies which did not bind to CC displayed an increase 
in product size approximate to the size of the transposon. This was an imprecise 
method of detection and limited the results of this study to proposing a best candidate 
which will need to be confirmed. Had all 12 colonies been fully sequenced this would 
have enabled the detection of the novel adhesion regardless of whether it was a beta 
barrel outer membrane protein or not.  
Future experiments considering the novel CC1 binding protein of MX13L should first 
sequence all of the colonies which did not bind CC1, in order to conclusively identify 
which protein is responsible for CC1 binding. 
An alternative method to identifying the target protein would have been to create KOs 
of the target genes in Moraxella catarrhalis and conduct binding assays to observe 
which of the newly created KOs did not bind to CC1.  
As the novel protein was found in MX13L this study focused on the singular strain of 
Moraxella catarrhalis and did not seek to identify if similar binding conditions could be 
observed in other strains which lacked a functional UspA region. Once the protein has 




to locate other strains of Moraxella catarrhalis which express the gene. This would 
help to understand if the protein is only present in strains which do not naturally 
express UspA proteins or if it is ubiquitous. If the gene for the protein was present in 
strains which did express UspA the next stage would be to identify if the protein was 
always being expressed or if it was only transcribed under certain conditions.  
 
 Further work 
Although this study identified a best candidate protein for a novel CC1 adhesin, this is 
only one small aspect. The completion of this project posed many more questions that 
should be examined in future studies. 
What is the main function of the novel adhesin, is it moonlighting as a CC1 bind protein 
whilst having another function? Is this protein an evolutionary remnant that came 
before Moraxella catarrhalis evolved the UspA genes? 
Examining other strains which also express the novel protein would further the 
understanding of the protein’s overall function, a purely redundant protein seems 
unlikely so expressing the protein even in the presence of UspA would probably 
indicate that the protein had an additional function.  
Does the presence of this protein indicate increased pathogenicity of the strain? Is it 
present in a specific type of Moraxella catarrhalis infection i.e. acute, coinfection or 
sepsis? Does the presence of this protein indicate increased virulence of the strain? 
Once the novel protein has been confirmed, it would be possible to raise an antibody 




the protein. Screening clinical isolates from different infection sites i.e. bacteraemia 
associated infection, for the presence of the novel adhesin would help determine if 
strains producing the protein are involved in more infections.  
 
Does this protein represent a suitable vaccine target? Will it produce a protective 
antibody response? 
After identification of the protein it would be beneficial to determine if it has any 
therapeutic relevance, outer membrane proteins which are widely distributed between 
bacterial strains are attractive vaccine targets. This protein should be analysed for a 














8 APPENDIX  
 
 Appendix 1: Primers 



















































































































 Appendix 2: Dot blots assessing the CC1 affinity of randomly generated 























































Dot blots assessing the CC1 affinity of randomly generated MX13L genetic knockouts.   
A dot blot was performed to assess the CC1 binding capabilities of the MX13L knockouts created by 
the ez tn5 transposon. 5760 colony picks were performed, and hand dotted onto nitrocellulose 
membrane (dots 1-5760). The lysates of selected Moraxella catarrhalis strains; MX13L, MX13D, 
ATCC25240, MX2, as wells as rD-7 & OpaLess (dots 5761-5766) acted as a series of standards to 
compare the binding of the colony picks. The membranes were primarily overlaid with 0.2 μg.mL-1 of 
CC1, before the secondary antibody 1 μg.mL-1 Rabbit-anti-Human-IgG(Fc)-AP was applied. Of the total 
dots examined only 8% displayed binding weaker than that of MX13D and were somewhat comparable 
to OpaLess. Dots which were comparable to OpaLess as well as unreliable dots were passed onto the 






9 REFERENCES  
Agnew, C., Borodina, E., Zaccai, N., Conners, R., Burton, N., Vicary, J., Cole, D., 
Antognozzi, M., Virji, M. and Brady, R. (2011). Correlation of in situ 
mechanosensitive responses of the Moraxella catarrhalis adhesin uspa1 with 
fibronectin and receptor CEACAM1 binding. Proceedings of the National Academy of 
Sciences, 108(37), pp.15174-15178. 
Ariza-Prota, M., Pando-Sandoval, A., García-Clemente, M., Fole-Vázquez, D. and 
Casan, P. (2016). Community-Acquired Moraxella catarrhalis Bacteria Pneumonia: 
Two Case Reports and Review of the Literature. Case Reports in Pulmonology, 
2016, pp.1-3. 
Attia, A., Ram, S., Rice, P. and Hansen, E. (2006). Binding of Vitronectin by the 
Moraxella catarrhalis uspa2 Protein Interferes with Late Stages of the Complement 
Cascade. Infection and Immunity, 74(3), pp.1597-1611. 
Berger, U. (1963). Die anspruchslosen Neisserien. Ergebnisse der Mikrobiologie 
Immunitatsforschung und Experimentellen Therapie, 36, pp.97-167. 
Bernardini, M.L., Sanna, M.G., Fontaine, A. and Sansonetti, P.J., 1993. Ompc is 
involved in invasion of epithelial cells by Shigella flexneri. Infection and Immunity, 
61(9), pp.3625-3635. 
Blakeway, L., Tan, A., Peak, I. and Seib, K. (2017). Virulence determinants of 
Moraxella catarrhalis: distribution and considerations for vaccine development. 




Bootsma, H., van der Heide, H., van de Pas, S., Schouls, L. and Mooi, F. (2000). 
Analysis of Moraxella catarrhalis by DNA Typing: Evidence for a Distinct 
Subpopulation Associated with Virulence Traits. The Journal of Infectious Diseases, 
181(4), pp.1376-1387. 
Bootsma, H., van Dijk, H., Verhoef, J., Fleer, A. and Mooi, F. (1996). Molecular 
characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis. 
Antimicrobial Agents and Chemotherapy, 40(4), pp.966-972. 
Bovre, K. (1979). Proposal to divide the genus Moraxella two subgenera, subgenus 
Moraxella and subgenus Branhamella. International Journal of Systematic 
Bacteriology, 29(4), pp.403-406. 
British Lung Foundation (2019). Chronic obstructive pulmonary disease (COPD) 
statistics | British Lung Foundation. [online] Statistics.blf.org.uk. Available at: 
https://statistics.blf.org.uk/copd [Accessed 16 Aug. 2019]. 
Catlin, B. (1970). Transfer of the Organism Named Neisseria Catarrhalis to 
Branhamella Gen. Nov. International Journal of Systematic Bacteriology, 20(2), 
pp.155-159. 
Catlin, B. (1990). Branhamella catarrhalis: an organism gaining respect as a 
pathogen. Clinical Microbiology Reviews, 3(4), pp.293-320. 
Conners, R., Hill, D., Borodina, E., Agnew, C., Daniell, S., Burton, N., Sessions, R., 
Clarke, A., Catto, L., Lammie, D., Wess, T., Brady, R. and Virji, M. (2008). The 
Moraxella adhesin uspa1 binds to its human CEACAM1 receptor by a deformable 




Constantinescu, M. (2019). Moraxella catarrhalis Infection: Background, 
Pathophysiology and Etiology, Epidemiology. [online] Emedicine.medscape.com. 
Available at: https://emedicine.medscape.com/article/222320-overview [Accessed 16 
Aug. 2019]. 
Cotter, S., Surana, N. and St. Geme, J. (2005). Trimeric autotransporters: a distinct 
subfamily of autotransporter proteins. Trends in Microbiology, 13(5), pp.199-205. 
De Vries, S., Bootsma, H., Hays, J. and Hermans, P. (2009). Molecular Aspects of 
Moraxella catarrhalis Pathogenesis. Microbiology and Molecular Biology Reviews, 
73(3), pp.389-406. 
De Vries, S., Eleveld, M., Hermans, P. and Bootsma, H. (2013). Characterization of 
the Molecular Interplay between Moraxella catarrhalis and Human Respiratory Tract 
Epithelial Cells. Plos ONE, 8(8), p.e72193. 
Earl, J., de Vries, S., Ahmed, A., Powell, E., Schultz, M., Hermans, P., Hill, D., Zhou, 
Z., Constantinidou, C., Hu, F., Bootsma, H. and Ehrlich, G. (2016). Comparative 
Genomic Analyses of the Moraxella catarrhalis serosensitive and Seroresistant 
Lineages Demonstrate Their Independent Evolution. Genome Biology and Evolution, 
8(4), pp.955-974. 
Forsgren, A., Brant, M., Möllenkvist, A., Muyombwe, A., Janson, H., Woin, N. and 
Riesbeck, K. (2001). Isolation and Characterization of a Novel IgD-Binding Protein 
from Moraxella catarrhalis. The Journal of Immunology, 167(4), pp.2112-2120. 
Francis, N., Cannings-John, R., Waldron, C., Thomas-Jones, E., Winfield, T., 




And Butler, C. (2018). Oral steroids for resolution of otitis media with effusion in 
children (OSTRICH): a double-blinded, placebo-controlled randomised trial. The 
Lancet, 392(10147), pp.557-568. 
Gehling, U.M., Ergün, S., Schumacher, U., Wagener, C., Pantel, K., Otte, M., 
Schuch, G., Schafhausen, P., Mende, T., Kilic, N. and Kluge, K., 2000. In vitro 
differentiation of endothelial cells from AC133-positive progenitor cells. Blood, The 
Journal of the American Society of Hematology, 95(10), pp.3106-3112. 
Genecards (2019). CEACAM1 Gene - genecards | CEAM1 Protein | CEAM1 
Antibody. [online] Genecards.org. Available at: https://www.genecards.org/cgi-
bin/carddisp.pl?Gene=CEACAM1 [Accessed 17 Aug. 2019]. 
Grandi, G., 2010. Bacterial surface proteins and vaccines. F1000 Biology Reports, 2. 
Gray-Owen, S. And Blumberg, R. (2006). CEACAM1: contact-dependent control of 
immunity. Nature Reviews Immunology, 6(6), pp.433-446. 
Guérin, J., Bigot, S., Schneider, R., Buchanan, S. and Jacob-Dubuisson, F. (2017). 
Two-Partner Secretion: Combining Efficiency and Simplicity in the Secretion of Large 
Proteins for Bacteria-Host and Bacteria-Bacteria Interactions. Frontiers in Cellular 
and Infection Microbiology, 7. 
Hammarström, S. (1999). The carcinoembryonic antigen (CEA) family: structures, 
suggested functions and expression in normal and malignant tissues. Seminars in 




Hassel, J., Lipski, S. and Lafontaine, E. (2007). Moraxella catarrhalis Strain O35E 
Expresses Two Filamentous Hemagglutinin-Like Proteins That Mediate Adherence 
to Human Epithelial Cells. Infection and Immunity, 75(6), pp.2765-2775. 
Hill, D. and Virji, M. (2003). A novel cell-binding mechanism of Moraxella catarrhalis 
ubiquitous surface protein uspa: specific targeting of the N-domain of 
carcinoembryonic antigen-related cell adhesion molecules by uspa1. Molecular 
Microbiology, 48(1), pp.117-129. 
Hill, D., Edwards, A., Rowe, H. and Virji, M. (2005). Carcinoembryonic antigen-
related cell adhesion molecule (CEACAM)-binding recombinant polypeptide confers 
protection against infection by respiratory and urogenital pathogens. Molecular 
Microbiology, 55(5), pp.1515-1527. 
Hill, D., Whittles, C. and Virji, M. (2012). A Novel Group of Moraxella catarrhalis uspa 
Proteins Mediates Cellular Adhesion via ceacams and Vitronectin. Plos ONE, 7(9), 
p.e45452. 
Hoiczyk, E. (2000). Structure and sequence analysis of Yersinia yada and Moraxella 
uspas reveal a novel class of adhesins. The EMBO Journal, 19(22), pp.5989-5999. 
Holm, M., Vanlerberg, S., Sledjeski, D. and Lafontaine, E., 2003. The Hag Protein of 
Moraxella catarrhalis Strain O35E Is Associated with Adherence to Human Lung and 
Middle Ear Cells. Infection and Immunity, 71(9), pp.4977-4984. 
Holme, T., Rahman, M., Jansson, P. and Widmalm, G. (1999). The 
lipopolysaccharide of Moraxella catarrhalis . Structural relationships and antigenic 




Ioannidis, J., Worthington, M., Griffiths, J. and Snydman, D. (1995). Spectrum and 
Significance of Bacteremia Due to Moraxella catarrhalis. Clinical Infectious Diseases, 
21(2), pp.390-397. 
Kaur R, Morris M, Pichichero ME. Epidemiology of Acute Otitis Media in the 
Postpneumococcal Conjugate Vaccine Era. Pediatrics. 2017;140(3):e20170101. 
Pediatrics. 2018;141(3):e20174067. Doi:10.1542/peds.2017-4067 
Khan, M., Northwood, J., Levy, F., Verhaegh, S., Farrell, D., Van Belkum, A. and 
Hays, J. (2009). Bro β-lactamase and antibiotic resistances in a global cross-
sectional study of Moraxella catarrhalis from children and adults. Journal of 
Antimicrobial Chemotherapy, 65(1), pp.91-97. 
Lacy, M., Berk, J. and Berk, S. (2017). Moraxella catarrhalis - Infectious Disease and 
Antimicrobial Agents. [online] Antimicrobe.org. Available at: 
http://antimicrobe.org/b114.asp [Accessed 16 Aug. 2019]. 
Lafontaine, E., Cope, L., Aebi, C., Latimer, J., mccracken, G. and Hansen, E. (2000). 
The uspa1 Protein and a Second Type of uspa2 Protein Mediate Adherence of 
Moraxella catarrhalis to Human Epithelial Cells In Vitro. Journal of Bacteriology, 
182(5), pp.1364-1373. 
Leung, J., Tiew, P., Mac Aogáin, M., Budden, K., Yong, V., Thomas, S., Pethe, K., 
Hansbro, P. and Chotirmall, S. (2017). The role of acute and chronic respiratory 





Linke, D., Riess, T., Autenrieth, I., Lupas, A. and Kempf, V. (2006). Trimeric 
autotransporter adhesins: variable structure, common function. Trends in 
Microbiology, 14(6), pp.264-270. 
Lipski, S., Akimana, C., Timpe, J., Wooten, R. and Lafontaine, E. (2006). The 
Moraxella catarrhalis Autotransporter mcap Is a Conserved Surface Protein That 
Mediates Adherence to Human Epithelial Cells through Its N-Terminal Passenger 
Domain. Infection and Immunity, 75(1), pp.314-324. 
Lisboa, F., Warren, J., Sulkowski, G., Aparicio, M., David, G., Zudaire, E. and 
Dveksler, G. (2010). Pregnancy-specific Glycoprotein 1 Induces Endothelial 
Tubulogenesis through Interaction with Cell Surface Proteoglycans. Journal of 
Biological Chemistry, 286(9), pp.7577-7586. 
Loosmore, S.M., Yang, Y.P., Coleman, D.C., Shortreed, J.M., England, D.M. and 
Klein, M.H., 1997. Outer membrane protein D15 is conserved among Haemophilus 
influenzae species and may represent a universal protective antigen against invasive 
disease. Infection and Immunity, 65(9), pp.3701-3707. 
Luke, N. R., Jurcisek, J. A., Bakaletz, L. O., & Campagnari, A. A. (2007). 
Contribution of Moraxella catarrhalis type IV pili to nasopharyngeal colonization and 
biofilm formation. Infection and immunity, 75(12), 5559–5564. 
Https://doi.org/10.1128/IAI.00946-07 
Luke, N., Jurcisek, J., Bakaletz, L. and Campagnari, A. (2007). Contribution of 
Moraxella catarrhalis Type IV Pili to Nasopharyngeal Colonization and Biofilm 




Luke-Marshall, N., Sauberan, S. and Campagnari, A. (2011). Comparative analyses 
of the Moraxella catarrhalis type-IV pilus structural subunit pila. Gene, 477(1-2), 
pp.19-23. 
Malmvall, B., Brorsson, J. and Johnsson, J. (1977). In vitro sensitivity to penicillin V 
and β-lacta-mase production of Branhamella catarrhalis. Journal of Antimicrobial 
Chemotherapy, 3(4), pp.374-374. 
Martin, J., Ball, L., Solomon, T., Dewald, A., Criss, A. and Columbus, L. (2016). 
Neisserial Opa Protein–CEACAM Interactions: Competition for Receptors as a 
Means of Bacterial Invasion and Pathogenesis. Biochemistry, 55(31), pp.4286-4294. 
Mcmichael, J., Fiske, M. and Fredenburg, R. (1998). Isolation and characterization of 
two proteins from Moraxella catarrhalis that bear a common epitope. Infect Immun., 
66(9), p.v. 
Mikula, K., Leo, J., Lyskowski, A., Kedracka-Krok, S., Pirog, A. and Goldman, A. 
(2011). The Translocation Domain in Trimeric Autotransporter Adhesins Is 
Necessary and Sufficient for Trimerization and Autotransportation. Journal of 
Bacteriology, 194(4), pp.827-838. 
Murphy, T. (1998). Lung infections. 2. Branhamella catarrhalis: epidemiological and 
clinical aspects of a human respiratory tract pathogen. Thorax, 53(2), pp.124-128. 
Murphy, T. and Parameswaran, G. (2009). Moraxella catarrhalis,a Human 




Murphy, T., Kirkham, C. and Lesse, A. (1993). The major heat-modifiable outer 
membrane protein CD is highly conserved among strains of Branhamella catarrhalis. 
Molecular Microbiology, 10(1), pp.87-97. 
Nordström, T., Blom, A., Forsgren, A. and Riesbeck, K. (2004). The Emerging 
Pathogen Moraxella catarrhalis Interacts with Complement Inhibitor C4b Binding 
Protein through Ubiquitous Surface Proteins A1 and A2. The Journal of Immunology, 
173(7), pp.4598-4606. 
Nordström, T., Blom, A., Forsgren, A. and Riesbeck, K., 2004. The Emerging 
pathogenMoraxella catarrhalisinteracts with Complement Inhibitor C4b Binding 
Protein through Ubiquitous Surface Proteins A1 and A2. The Journal of Immunology, 
173(7), pp.4598-4606. 
Nummelin, H., Merckel, M., Leo, J., Lankinen, H., Skurnik, M. and Goldman, A. 
(2004). The Yersinia adhesin yada collagen-binding domain structure is a novel left-
handed parallel β-roll. The EMBO Journal, 23(4), pp.701-711. 
Parameswaran, G., Wrona, C., Murphy, T. and Sethi, S. (2009). Moraxella 
catarrhalisacquisition, airway inflammation and protease-antiprotease balance in 
chronic obstructive pulmonary disease. BMC Infectious Diseases, 9(1). 
Pearson, M., Lafontaine, E., Wagner, N., St. Geme III, J. and Hansen, E. (2002). A 
hag Mutant of Moraxella catarrhalis Strain O35E Is Deficient in Hemagglutination, 





Perez, A. and Murphy, T. (2017). A Moraxella catarrhalis vaccine to protect against 
otitis media and exacerbations of COPD: An update on current progress and 
challenges. Human Vaccines & Immunotherapeutics, 13(10), pp.2322-2331. 
Perez, A. and Murphy, T., 2017. A Moraxella catarrhalis vaccine to protect against 
otitis media and exacerbations of COPD: An update on current progress and 
challenges. Human Vaccines & Immunotherapeutics, 13(10), pp.2322-2331. 
Perez, A. and Murphy, T., 2019. Potential impact of a Moraxella catarrhalis vaccine in 
COPD. Vaccine, 37(37), pp.5551-5558. 
Perez, A., Pang, B., King, L., Tan, L., Murrah, K., Reimche, J., Wren, J., Richardson, 
S., Ghandi, U. and Swords, W., 2014. Residence of Streptococcus pneumoniaenand 
Moraxella catarrhalis within polymicrobial biofilm promotes antibiotic resistance and 
bacterial persistence in vivo. Pathogens and Disease, 70(3), pp.280-288. 
Pettersson, B., Kodjo, A., Ronaghi, M., Uhlen, M. and Tonjum, T. (1998). Phylogeny 
of the family Moraxellaceae by 16S rdna sequence analysis, with special emphasis 
on differentiation of Moraxella species. International Journal of Systematic 
Bacteriology, 48(1), pp.75-89. 
Plosker GL. 13-valent pneumococcal conjugate vaccine: a review of its use in 
infants, children, and adolescents. Paediatr Drugs. 2013;15(5):403-423. 
Doi:10.1007/s40272-013-0047-z 
Ramadan, M., Ibrahim, I., Shaheen, A. and Ali, W., 2017. Significance of Moraxella 
catarrhalis as a causative organism of lower respiratory tract infections. Egyptian 




Rämer, P., Chijioke, O., Meixlsperger, S., Leung, C. and Münz, C., 2011. Mice with 
human immune system components as in vivo models for infections with human 
pathogens. Immunology & Cell Biology, 89(3), pp.408-416. 
Raynes, J., Young, P., Proft, T., Williamson, D., Baker, E. and Moreland, N., 2018. 
Protein adhesins as vaccine antigens for Group A Streptococcus. Pathogens and 
Disease, 76(2). 
Ren, D. And Pichichero, M., 2015. Vaccine targets against Moraxella catarrhalis. 
Expert Opinion on Therapeutic Targets, 20(1), pp.19-33. 
Ruckdeschel, E., Brauer, A., Johnson, A. and Murphy, T., 2009. Characterization of 
proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis. Vaccine, 
27(50), pp.7065-7072. 
Schaar, V., Nordström, T., Mörgelin, M. and Riesbeck, K., 2011. Moraxella 
catarrhalis outer membrane vesicles carry β-lactamase and promote survival of 
Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin. 
Antimicrobial agents and chemotherapy, 55(8), pp.3845-3853. 
Schmitz, F., Beeck, A., Perdikouli, M., Boos, M., Mayer, S., Scheuring, S., Kohrer, 
K., Verhoef, J. and Fluit, A. (2002). Production of BRO -Lactamases and Resistance 
to Complement in European Moraxella catarrhalis Isolates. Journal of Clinical 
Microbiology, 40(4), pp.1546-1548. 
Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of 




Shaffer, T., Balder, R., Buskirk, S., Hogan, R. and Lafontaine, E., 2013. Use of the 
Chinchilla Model to Evaluate the Vaccinogenic Potential of the Moraxella catarrhalis 
Filamentous Hemagglutinin-like Proteins mhab1 and mhab2. Plos ONE, 8(7), 
p.e67881. 
Shi, W., Wen, D., Chen, C., Yuan, L., Gao, W., Tang, P., Cheng, X. and Yao, K. 
(2018). Β-Lactamase production and antibiotic susceptibility pattern of Moraxella 
catarrhalis isolates collected from two county hospitals in China. BMC Microbiology, 
18(1). 
Sillanpää, S., Oikarinen, S., Sipilä, M., Kramna, L., Rautiainen, M., Huhtala, H., 
Aittoniemi, J., Laranne, J., Hyöty, H. and Cinek, O., 2016. Moraxella catarrhalis 
might be more common than expected in acute otitis media in young Finnish 
children. Journal of clinical microbiology, 54(9), pp.2373-2379. 
Smidt, M., Bättig, P., Verhaegh, S., Niebisch, A., Hanner, M., Selak, S., Schüler, W., 
Morfeldt, E., Hellberg, C., Nagy, E., Lundberg, U., Hays, J., Meinke, A. and Henriques-
Normark, B., 2013. Comprehensive Antigen Screening Identifies Moraxella catarrhalis 
Proteins That Induce Protection in a Mouse Pulmonary Clearance Model. Plos ONE, 
8(5), p.e64422. 
Spaniol, V., Heiniger, N., Troller, R. and Aebi, C., 2008. Outer membrane protein 
uspa1 and lipooligosaccharide are involved in invasion of human epithelial cells by 
Moraxella catarrhalis. Microbes and infection, 10(1), pp.3-11. 
Szczesny P, Lupas A. Domain annotation of trimeric autotransporter adhesins--




Tchoupa AK, Lichtenegger S, Reidl J, Hauck CR. Outer membrane protein P1 is the 
CEACAM-binding adhesin of Haemophilus influenzae. Mol Microbiol. 
2015;98(3):440-455. Doi:10.1111/mmi.13134 
Tchoupa, A. K., Schuhmacher, T., & Hauck, C. R. (2014). Signaling by epithelial 
members of the CEACAM family - mucosal docking sites for pathogenic bacteria. 
Cell communication and signaling : CCS, 12, 27. Https://doi.org/10.1186/1478-811X-
12-27 
Thibau, A., Dichter, A., Vaca, D., Linke, D., Goldman, A. and Kempf, V., 2019. 
Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine 
targets. Medical Microbiology and Immunology, 209(3), pp.243-263. 
Vaneechoutte, M., Verschraegen, G., Claeys, G., Weise, B.A.R.B.A.R.A. and Van 
den Abeele, A.M., 1990. Respiratory tract carrier rates of Moraxella (Branhamella) 
catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis 
from sputum. Journal of clinical microbiology, 28(12), pp.2674-2680. 
Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A. Moraxella catarrhalis: from 
emerging to established pathogen. Clin Microbiol Rev. 2002;15(1):125-144. 
Doi:10.1128/cmr.15.1.125-144.2002 
Villullas, S., Hill, D.J., Sessions, R.B., Rea, J. and Virji, M., 2007. Mutational analysis 
of human CEACAM1: the potential of receptor polymorphism in increasing host 
susceptibility to bacterial infection. Cellular microbiology, 9(2), pp.329-346. 





Williamson, I., Benge, S., Barton, S., Petrou, S., Letley, L., Fasey, N., Haggard, M. 
and Little, P., 2009. Topical intranasal corticosteroids in 4-11 year old children with 
persistent bilateral otitis media with effusion in primary care: double blind 
randomised placebo controlled trial. BMJ, 339, p.b4984. 
Wirth, T., Morelli, G., Kusecek, B., van Belkum, A., van der Schee, C., Meyer, A., & 
Achtman, M. (2007). The rise and spread of a new pathogen: seroresistant 
Moraxella catarrhalis. Genome research, 17(11), 1647–1656. 
Https://doi.org/10.1101/gr.6122607 
 
 
 
 
 
